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α the factor by which Km changes when an inhibitor occupies the enzyme
Ah aryl hydrocarbon
AUC(0-t) area under the curve for concentration or effect versus time from 0 to t hours
CAR constitutive androstane receptor
CE drug concentration around the metabolic enzyme site
Clh hepatic clearance
Clint total intrinsic clearance
Clint, u unbound intrinsic clearance
Cmax peak plasma concentration
Clmet partial metabolic clearance
CYP cytochrome P450
DDC diethyldithiocarbamate
DMSO dimethyl sulfoxide
E hepatic extraction ratio
FDCL the fractional decrement of clearance in vivo
FDV the fractional decrement of reaction velocity in vitro
Foral oral bioavailability
fu unbound fraction of drug in the blood
Hlc human liver cytosol
HPLC high-performance liquid chromatography
Hsa human serum albumin
i degree of inhibition
I inhibitor concentration
Iu unbound concentration of inhibitor
IC50 concentration of inhibitor corresponding to a 50% decrease in reaction velocity
Ki inhibition constant
KI the concentration of mechanism-based inhibitor required for half-maximal
inactivation
Kinact the rate constant of inactivation
Km Michaelis-Menten constant represents the total substrate concentration at
which the reaction velocity is 50% of maximum
Km, u unbound Michaelis-Menten constant represents the unbound substrate
concentration at which the reaction velocity is 50% of maximum
Kobs apparent inactivation rate constant
MI metabolite intermediate
MM Michaelis-Menten
n Hill coefficient for cooperative substrate binding
NADPH reduced nicotinamide adenine dinucleotide phosphate
P-gp P-glycoprotein
PM poor metabolism
PPAR peroxisome proliferator activated receptor
9PXR pregnane X receptor
Q hepatic blood flow
S substrate concentration
SSRI selective serotonin reuptake inhibitors
S50 the substrate concentration at which half the maximal rate is attained in the Hill
equation
TAO troleandomycin
t1/2 elimination half-life
T1/2 apparent half-life for mechanism-based inactivation
tmax time to peak plasma concentration
UGT uridine diphosphate-glucuronosyltransferases
Vmax the maximum velocity of metabolite formation based on total substrate
concentration
Vmax, u the maximum velocity of metabolite formation based on unbound substrate
concentration
V0 the velocity of an enzyme reaction in the absence of inhibitor
Vi the velocity of an enzyme reaction in the presence of inhibitor
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ABSTRACT
In vitro systems have been widely used in evaluating potential drug-drug interactions
in vivo. In the present studies, the effects of valproic acid, gemfibrozil, isoniazid,
trimethoprim and sulfamethoxazole on the CYP forms (CYP1A2, 2A6, 2C8, 2C9,
2C19, 2D6, 2E1 and 3A4) activities were examined in vitro using pooled human liver
microsomes or recombinant CYP forms. The IC50 and Ki values were characterized
using an apparent reversible inhibition. The KI and Kinact values were characterized
using a mechanism-based inhibition. The in vivo degrees of inhibition (i) were
predicted in vitro using a scaling model: i = I/(I + Ki). In addition, the effects of human
serum albumin (Hsa) and human liver cytosol (Hlc) on the in vitro enzyme kinetic
estimates of the formation of hydroxytolbutamide, and on the inhibitory effect of
gemfibrozil on tolbutamide hydroxylase activity were evaluated using human liver
microsomes.
Valproic acid preferentially inhibited CYP2C9 activity (Ki = 600 µM), while it
exhibited minimal or no inhibitory effects on the other CYP forms evaluated.
Gemfibrozil inhibited CYP2C9 (Ki = 5.8 µM), and CYP2C19 (Ki = 24 µM) and
CYP1A2 (Ki = 82 µM) activities. Isoniazid was a mechanism-based inhibitor of
CYP1A2, 2A6, 2C19 and 3A4 forms, with Kinact values of 0.11, 0.13, 0.09, and 0.08
min-1, and KI values of 285, 173, 112, and 228 µM, respectively. Trimethoprim (5-100
µM) selectively inhibited CYP2C8 activity (Ki = 32 µM), while sulfamethoxazole (50-
500 µM) selectively inhibited CYP2C9 activity (Ki = 271 µM). Based on the
aforementioned scaling model and the unbound plasma concentrations of the drugs,
inhibition of CYP2C9 (7%) by valproic acid, CYP2C9 (56%), CYP2C19 (24%) and
CYP1A2 (8%) by gemfibrozil, CYP2C8 (26%) by trimethoprim, and CYP2C9 (24%)
by sulfamethoxazole would be expected in vivo. The addition of Hsa and Hlc to the
incubation media distinctly changed the kinetic estimates of tolbutamide
hydroxylation, with the predicted in vivo hepatic clearance (Clh) of tolbutamide
hydroxylation (0.14 ml/min/kg) comparable to the actual in vivo value (0.15
ml/min/kg). However, the unbound Ki of gemfibrozil for CYP2C9 (6 µM in the
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absence of Hsa and Hlc in the incubation media) was not markedly altered by Hsa (4
µM), Hlc (8 µM) or both Hsa and Hlc (9 µM) when the unbound substrate and
inhibitor concentrations were considered.
The results of the present studies indicated that in vitro, valproic acid reversibly
inhibits CYP2C9 and gemfibrozil inhibits CYP2C9, 2C19 and 1A2; isoniazid is a
mechanism-based inhibitor of CYP1A2, 2A6, 2C19 and 3A4; trimethoprim is a
selective inhibitor of CYP2C8 and sulfamethoxazole of CYP2C9. In humans, the
inhibition of these CYP activities by these drugs may result in significant drug-drug
interactions, and can explain some of their documented drug-drug interactions.
However, in most cases, confirmation of the predicted drug-drug interactions requires
further in vivo experiments. The addition of Hsa and Hlc to microsomal incubations
may yield enzyme kinetic estimates more comparable with in vivo results for CYP2C9
substrates. However, further experiments are needed to clarify the effects of Hsa and
Hlc on other CYP substrates and other CYP enzymes.
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INTRODUCTION
The cytochrome P450 (CYP) enzymes constitute a superfamily of hemoprotein
enzymes that are responsible for biotransformation of numerous xenobiotics, including
therapeutic agents. In humans, the major drug-metabolising CYPs belong to enzyme
families 1, 2 and 3, with the main CYP forms being 1A2, 2A6, 2C8, 2C9, 2C19, 2D6,
2E1 and 3A4 (Shimada et al. 1994). Inhibition and induction of these CYP enzymes
may result in toxicity or therapeutic failure, and are the most common causes for drug-
drug interactions (see Lin & Lu 1998; Venkatakrishnan et al. 2001).
Because of limitation of in vivo studies and problems in extrapolating the results of
animal studies to humans, in vitro systems using human tissues have become widely
used as tools to evaluate potential drug-drug interactions in humans (see Levy et al.
2000). In vitro systems include enzyme-based systems (liver microsomes and cDNA-
expressed enzymes systems) and cell-based systems (hepatocytes and liver slices)
(Wrighton et al. 1993; Ekins et al. 2000). Among these, the human liver microsomal
system has been confirmed to be the most feasible and well set up system for drug
metabolism and interactions studies (see Levy et al. 2000; Venkatakrishnan et al.
2001).
Although the use of microsomal studies for quantitative or semi-quantitative prediction
of in vivo drug inhibitions is promising, several factors can significantly affect the
results of microsomal studies, resulting in an inability to accurately predict the in vivo
situation (Newton et al. 1995; von Moltke et al. 1995a). For example, the nonspecific
microsomal binding of substrates to in vitro incubation matrices may result in an
underprediction of the in vivo hepatic clearance (Clh) due to a reduced rate of in vitro
metabolism (Obach 1999). In addition, it was recently reported that the addition of
bovine serum albumin or rat liver cytosol to the microsomal incubation medium could
promote CYP2C9-mediated reactions (Ludden et al. 1997; Carlile et al. 1999;
Komatsu et al. 2000a). However, the mechanisms involved in this phenomenon are
INTRODUCTION
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still far from clear, and require further exploration with other substrates and other CYP
forms.
Valproic acid, gemfibrozil, isoniazid, trimethoprim and sulfamethoxazole are widely
used therapeutic agents. These drugs can affect the pharmacokinetics of several drugs,
which are metabolised by different CYP forms. For example, valproic acid affects the
pharmacokinetics of phenytoin, amitriptyline, phenobarbital and diazepam (Perucca et
al. 1980; Wong et al. 1996; Patel et al. 1980; Dhillon et al. 1982); gemfibrozil
enhances the anticoagulant effect of warfarin, resulting in severe
hypoprothrombinemia and bleeding, and it interacts with glyburide and glimepiride,
resulting in hypoglycaemia (Ahmad 1990; 1991; Rindone & Keng 1998; Niemi et al.
2001). A combined therapy of gemfibrozil and statins such as atorvastatin, cervastatin,
lovastatin or simvastatin in patients can result in severe myopathy and rhabdomyolysis
(Murdock et al. 1999); isoniazid decreases the elimination of several drugs including
carbamazepine, diazepam, triazolam, vincristine, theophylline, disulfiram,
chlorzoxazone and paracetamol (Wright et al. 1982; Ochs et al. 1981; 1983; Chan et
al. 1998; Samigun et al. 1990; Whittington et al. 1969; Zand et al. 1993); trimethoprim
and sulfamethoxazole interact with tolbutamide, phenytoin, warfarin, and glipizide
(Wing & Miners 1985; Hansen et al. 1979; O'Reilly 1980; Johnson et al. 1990).
However, comprehensive studies on the inhibition of major CYP forms by these drugs
have not been published.
In the present series of studies, the inhibitory effects of the aforementioned drugs on
CYP activities were investigated in human liver microsomes (or recombinant CYP
forms). Using selective marker reactions for the major CYP forms, prediction of the
potential in vivo drug-drug interactions was carried out using an in vitro-in vivo scaling
model. In addition, the effects of the addition of human serum albumin (Hsa) or human
liver cytosol (Hlc) to microsomal incubation media on the enzyme kinetic estimates of
the formation of hydroxytolbutamide (a marker reaction of CYP2C9), and on the
inhibitory effect of gemfibrozil on tolbutamide hydroxylase activity were examined
using human liver microsomes.
REVIEW OF THE LITERATURE
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REVIEW OF THE LITERATURE
1. Drug metabolism and CYP enzymes
1.1 Drug metabolism
Most drugs are lipophilic compounds, which need to be enzymatically transformed
into more polar, water-soluble, and excretable metabolites that can be easily
eliminated from organisms (see Stockley 1999; Meyer 1996). The biotransformation
of drugs can be classified into phase I and phase II reactions. Phase I metabolism
includes oxidation, reduction and hydrolysis reactions, while phase II reactions include
glucuronidation, acetylation, sulfation, methylationand, and glutathione and amino
acids conjugation. Usually phase II reactions generate inactive and more water-soluble
compounds that can be easily eliminated from an organism via urine or bile (see
Gonzalez & Idle 1994; Lin & Lu 2001).
The major site of biotransformation of drugs is the liver, which contains a large
number of metabolising enzymes. In addition, enzymes in the intestinal mucosa also
contribute significantly to the metabolism of drugs (see Hall et al. 1999). Other
extrahepatic sites of drug metabolism include the kidneys, lungs, skin, brain and nasal
epithelium. However, these sites contribute to a minor extent to the systemic
elimination of drugs compared with the liver and intestines (see Krishna & Klotz
1994).
1.2 CYP enzymes in man
Cytochrome P450 (CYP) enzymes, are the most important phase I enzymes that are
involved in the metabolism of many endogenous compounds and a majority of
clinically used drugs (see Gonzalez & Idle 1994). CYP proteins, named according to
the absorption band at 450 nm of their reduced carbon-monoxide-bound forms, consist
of large superfamilies of enzyme proteins (see Schenkman & Jansson 1999). The root
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symbol, CYP, is followed by a number for the family (a general group of protein with
more than 40% amino-acid sequence identity), a letter for the subfamily (greater than
55% identity), and a number for the gene denoting a specific CYP form. Distinct CYP
forms differ from each other with respect to their chemical, immunological properties,
and they have different substrate affinities (see Meyer 1996). Intracellularly, the CYP
enzymes are found primarily in the endoplasmic reticulum that also serves as the locus
of metabolic drug interactions (see Lin & Lu 1998). The CYP enzymes are synthesized
on membrane-bound polyribosomes and inserted directly into the lipid bilayer
(Gonzalez & Kasper 1980; Sabatini et al. 1982).
In mammals, at least 17 CYP gene families have been identified. Among these, the
CYP1, CYP2, and CYP3 subfamilies are mainly involved in the biotransformation of
pharmaceuticals and xenobiotics. The other CYP families mainly take part in the
biosynthesis of steroids, metabolism of bile acids and arachidonic acid, and
metabolism of other endogenous compounds (Nelson et al. 1996). The major drug
metabolising CYP subfamilies in humans are CYP3A (3A4 and 3A5) (∼30% of total
P450 content in the liver), CYP2C (2C8, 2C9, 2C18 and 2C19) (∼20%), CYP1A2
(∼13%), CYP2E1 (∼7%), CYP2A6 (∼4%), and CYP2D6 (∼2%) (Shimada et al. 1994).
Among these, several CYP forms, e.g. CYP2A6, 2C8, 2C9, 2C19, 2D6, and 2E1 are
polymorphic expressed in human subjects (see Raunio et al. 2001; Goldstein 2001;
Rodrigues 2002; Shimada et al. 1994; Levy et al. 2000).
1.2.1 CYP1A2 enzyme
The human CYP1A subfamily comprises two members, CYP1A1 and CYP1A2.
CYP1A1 is expressed at a very low level in the liver, while it is primarily an
extrahepatic enzyme found in the lungs and placenta (see Pelkonen et al. 1998). There
is genetic polymorphism in the inducibility of CYP1A1 by polycyclic aromatic
hydrocarbons, with a high inducibility phenotype being more common in patients with
lung cancer (Kouri et al. 1982; Nebert et al. 1991). CYP1A2 is the predominant
enzyme of the CYP1A subfamily constituting approximately 13% of the total CYP
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protein in human livers (Shimada et al. 1994). CYP1A2 activity can be induced by
cigarette smoking, resulting in an almost two-fold increase of the metabolic clearances
of substrates of this enzyme compared with nonsmokers (Grygiel et al. 1981). In
addition, omeprazole has been shown to be a dose-dependent inducer of CYP1A2 in
man (Andersson 1991).
In humans, the interindividual variability of the expression of CYP1A2 is large. For
example, about 40-60 fold differences between different ethnic groups have been
reported (Shimada et al. 1994). However, to date, no specific polymorphism of the
CYP1A2 gene has been identified (Catteau et al. 1995).
CYP1A2 is responsible for the metabolism of several drugs, including phenacetin,
caffeine, theophylline, paracetamol, olanzapine, lidocaine, and some procarcinogens
(see Zevin et al. 1999; Pelkonen et al. 1998; Wang et al. 2000a). The major route of
caffeine metabolism in man (N-3-demethylation of caffeine to paraxanthine) is
mediated by CYP1A2 (Lelo et al. 1986; Butler et al. 1989). Therefore, caffeine has
been used in vivo as a CYP1A2 probe substrate. In in vitro studies, ethoxyresorufin
and phenacetin have been used as preferential probe substrates (Distlerath et al. 1985;
Burke et al. 1994).
The selective serotonin reuptake inhibitors (SSRI) antidepressant fluvoxamine (Ki ∼
0.2 µM) (Nemeroff et al. 1996) and the fluoroquinolone antibiotics ciprofloxacin and
enoxacin, are the most significant CYP1A2 inhibitors which can cause clinically
significant drug-drug interactions with substrates of CYP1A2 (Schmider et al. 1997).
Although fluvoxamine has been used as a potent inhibitor of CYP1A2 in reaction
phenotyping studies in vivo, it also inhibits CYP2C19 with similar potency and may
cause clinically significant drug-drug interactions with CYP2C19 substrates (von
Moltke et al. 1999). Furafylline (a mechanism-based inhibitor of CYP1A2, KI = 3 ∼ 23
µM and Kinact = 0.07 ∼ 0.87 min-1) and α-naphthoflavone are used as relatively specific
and potent inhibitors of CYP1A2 in vitro (Newton et al. 1995; Bourrie et al. 1996)
(Table 1).
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1.2.2 CYP2A6 enzyme
CYP2A6 is a quantitatively minor component (1-5%) of the human hepatic CYP
forms. A number of compounds such as phenobarbital and pyrazole increased
CYP2A6 activity at the mRNA level in human hepatocytes in primary culture (Dalet-
Beluche et al. 1992; Donato et al. 2000). CYP2A6 is active in the metabolism of a few
drugs, such as coumarin, methoxyflurane, halothane, valproic acid, disulfiram,
losigamone, letrozole and a number of procarcingens (see Raunio et al. 1998; 2001;
Pelkonen et al. 2000; Oscarson 2001). In vitro studies using human liver microsomes
and recombinant CYP forms also indicated that CYP2A6 is the most important CYP
form responsible for the C-oxidation of nicotine (Nakajima et al. 1996; Messina et al.
1997).
In humans, CYP2A6 is polymorphically expressed. The polymorphism of CYP2A6
has been thought to be associated with smoking habits as well as the risk of lung
cancer (Pianezza et al. 1998; London et al. 1999). To date, several defective alleles of
CYP2A6 have been reported with the most prevalence of them being a Leu 160 His
substitution (CYP2A6*2) that yields an inactive enzyme (Fernandez-Salguero et al.
1995; Hadidi et al. 1997). By contrast, a deletion mutation (CYP2A6*4) is the most
common variant (15-20%) in Asian populations (Nunoya et al. 1998). Duplication of
the CYP2A6 gene also occurs and appears to be associated with increased catalytic
activity (Rao et al. 2000). Overall, the frequencies of all the major variant alleles of
CYP2A6 are rather uncommon in Caucasians, while some of these alleles are highly
prevalent in Oriental populations (Oscarson et al. 1999a; 1999b; Chen et al. 1999;
Nunoya et al. 1999).
Coumarin 7-hydroxylation is selectively catalyzed by CYP2A6, and coumarin has
therefore been used as a CYP2A6 probe drug both in vitro and in vivo (Rautio et al.
1992). Compounds including 8-methoxypsoralen, menthofuran, pilocarpine and
tranylcypromine have been found to be relatively potent inhibitors of CYP2A6
(Koenigs et al. 1997; Khojasteh-Bakht et al. 1998; Kinonen et al. 1995; Taavitsainen et
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al. 2001). Among these, 8-methoxypsoralen is a probe and potent mechanism-based
inhibitor of CYP2A6 (KI = 1.9 µM and Kinact = 2 min-1), which has been used as a
useful in vitro tool for evaluation of the contribution of CYP2A6 metabolic reactions
(Koenigs et al. 1997) (Table 1). In addition, tranylcypromine might be an adequately
selective CYP2A6 inhibitor for in vitro use (Taavitsainen et al. 2001; Zhang et al.
2001).
1.2.3 CYP2B6 enzyme
CYP2B6 comprises on average only about 0.2% of the total CYP in human livers, but
its expression has large interindividual variability (Levy et al. 2000). In primary
cultured human hepatocytes and in different human cell lines, CYP2B6 can be induced
at protein and mRNA levels by phenobarbital, and cyclophosphamide which is an
anticancer drug known to be metabolised by CYP2B6 (Gervot et al. 1999). CYP2B6
can be involved in the metabolism of a number of substrates such as, nicotine,
aminochrysene, tamoxifen, testosterone, diazepam, S-mephenytoin (N-demethylation),
S-mephobarbital, cyclophosphamide and propofol (Ekins et al. 1997; Kent et al. 1999;
Court et al. 2001) (Table 1). The activity of CYP2B6 can be inhibited by fluvoxamine,
sertraline and paroxetine (Hesse et al. 2000).
1.2.4 CYP2C enzymes
In human livers, the CYP2C subfamily is one of the most abundantly expressed CYP
subfamilies. It includes four known members: CYP2C8, 2C9, 2C18, and 2C19.
CYP2C8 and CYP2C9 are the major CYP2C forms, accounting for 35% and 60%,
respectively, of the total hepatic content of human CYP2C, while CYP2C18 (4%) and
CYP2C19 (1%) are the minor forms of the human CYP2C subfamily (Ged et al. 1988;
Romkes et al. 1991). It has been estimated that CYP2C8, CYP2C9, and CYP2C19 are
involved in the metabolism of approximately 20% of clinically used drugs (see
Richardson et al. 1996; Rodrigues 1999; 2002). Although the amino-acid sequences of
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CYP2C9 and CYP2C19 are 91% homologous, they exhibit relatively little overlap in
their substrate specificities (Wrighton & Stevens 1992).
1.2.4.1 CYP2C8 enzyme
The importance of CYP2C8 in drug metabolism has only recently been recognized
(Ong et al. 2000). CYP2C8 mRNA and protein can be induced by rifampicin and
phenobarbital in primary cultures of human hepatocytes (Gerbal-Chaloin et al. 2001).
CYP2C8 is primarily responsible for the metabolism of the anti-cancer drug taxol,
cerivastatin, rosiglitazone, troglitazone, and is also involved in the metabolism of
zopiclone, carbamazepine, verapamil, and amiodarone (Ong et al. 2000; Ohyama et al.
2000). It is also the predominant CYP responsible for the metabolism of arachidonic
acid to biologically active epoxyeicosatrienoic acids in human liver and kidney (Dai et
al. 2001).
CYP2C8 is polymorphically expressed in human livers (see Goldstein 2001). Two
CYP2C8 alleles containing coding changes have been found. CYP2C8*2 has an
Ile269Phe substitution in exon 5, and CYP2C8*3 includes both Arg139Lys and
Lys399Arg amino acid substitutions in exons 3 and 8 (Dai et al. 2001). CYP2C8*2
was found only in African-Americans with a frequency of 0.18, while CYP2C8*3
occurred primarily in Caucasians with a frequency of 0.13 (Dai et al. 2001). One of the
polymorphic alleles of CYP2C8 is defective in metabolising paclitaxel in vitro
(Rifkind et al. 1995; Zeldin et al. 1996). For example, CYP2C8*2 had a two-fold
higher Km (Michaelis-Menten constant) and a two-fold lower intrinsic clearance for
paclitaxel than CYP2C8*1 (wild-type) (Dai et al. 2001). Quercetin has been used in
vitro as an inhibitor of CYP2C8, but it also significantly inhibits CYP1A2 activity
(Dierks et al. 2001).
1.2.4.2 CYP2C9 enzyme
CYP2C9 is the principal CYP2C form in human liver. It metabolises many clinically
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important drugs including tolbutamide, phenytoin, S-warfarin, losartan, ibuprofen,
diclofenac, piroxicam, tenoxicam, and mefenamic acid (see Goldstein 2001). In
addition, the antidiabetic drug glipizide and the diuretic torsemide have been reported
to be metabolized by CYP2C9 (Kidd et al. 1999; Miners et al. 2000).
CYP2C9 has been found to be genetically polymorphic. Three naturally occurring
allelic variants of CYP2C9, that showed significantly altered catalytic properties, have
been identified: the wild-type Arg-144 Leu-359 (CYP2C9*1), Cys-144 Leu-359
(CYP2C9*2), and Arg-144 Ile-359 (CYP2C9*3) (see Miners et al. 1998). The
polymorphism of CYP2C9 differs across various ethnic groups. White subjects have
significantly higher frequencies of both CYP2C9*2 (∼ 10%) and *3 (∼ 10%) than
Asian (0 ∼ 2%) or black subjects (1∼ 3%) (Sullivan-Klose et al. 1996; Inoue et al.
1997; Aynacioglu et al. 1999). The genetic polymorphism of CYP2C9 seriously
affects the toxicity of drugs that are substrates of CYP2C9 with narrower therapeutic
indices. For example, the CYP2C9*3 variant exhibits a lower intrinsic clearance
(Vmax/Km) of tolbutamide, S-warfarin, phenytoin, piroxicam, and torsemide than the
wild-type CYP2C9*1 variant (Sullivan-Klose et al. 1996; Aynacioglu et al. 1999).
S-warfarin, tolbutamide and diclofenac have been used as in vitro probe substrates of
CYP2C9 (Doecke et al. 1991). Inhibitors of CYP2C9 include sulfaphenazole,
sulfamethoxazole, sulfinpyrazone, miconazole, and fluconazole (see Miners et al.
1998). Sulphaphenazole (Ki ∼ 0.3 µM) has been used as a selective inhibitor of
CYP2C9 in in vitro studies (Newton et al. 1995; Bourrie et al. 1996) (Table 1).
Inducers of CYP2C9 include barbiturates, carbamazepine, and rifampin (Treluyer et
al. 1997; Gerbal-Chaloin et al. 2001).
1.2.4.3 CYP2C18 enzyme
CYP2C18 expressed at a very low level in human livers, but CYP2C18 can
participate, to a small extent, in the metabolism of substrates of other CYP2C forms,
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such as diazepam, imipramine, and tolbutamide (Venkatakrishnan et al. 2001;
Komatsu et al. 2000b).
1.2.4.4 CYP2C19 enzyme
CYP2C19, is another important member of the CYP2C subfamily, it can be induced
by barbiturates, carbamazepine, and rifampin, phenytoin in primary cultures of human
hepatocytes (Gerbal-Chaloin et al. 2001). CYP2C19 is involved in the metabolism of
drugs including S-mephenytoin, omeprazole, diazepam, propranolol, proguanil and
tricyclic antidepressants, such as imipramine, clomipramine and amitriptyline (see
Levy et al. 2000).
CYP2C19 exhibits genetic polymorphism, with the poor metabolism (PM) phenotype
representing 2 to 6% of Caucasian populations, 12 to 23% of Oriental populations, and
2% in Black Americans (Wilkinson et al. 1989; Marinac et al. 1996; Meyer & Zanger
1997). The molecular genetic basis of the phenotypes is now well recognized. The two
most common defects involving null alleles arise from G → A base pair mutations in
exon 5 (CYP2C19*2) and exon 4 (CYP2C19*3), respectively, accounting for over
99% of defective alleles in Asian populations and 87% in Caucasians (de Morais et al.
1994; Brosen et al.1995). A transition mutation in the initiation codon (CYP2C19*4)
accounts for an additional 3% of defective alleles in Caucasians (Ferguson et al. 1998).
S-mephenytoin and omeprazole have been used as in vitro probe substrates of
CYP2C19 (de Morais et al. 1994; Brosen et al. 1995; Tucker et al. 2001). The
inhibitors of CYP2C19 include fluvoxamine, omeprazole, fluconazole (Ki ∼ 2 µM),
and ticlopidine (Kunze et al. 1996; Venkatakrishnan et al. 2001). Among these,
omeprazole is a relatively specific CYP2C19 inhibitor up to 10 µM, but higher
concentrations inhibit CYP2C9, 3A4 and 2D6 with lower potency (Ko et al. 1997;
Giancarlo et al. 2001) (Table 1).
1.2.5 CYP2D6 enzyme
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CYP2D6 constitutes on average about 2% to 5% of the total hepatic CYP content, and
it is also found in several extrahepatic tissues, including the gastrointestinal tract,
brain, and lungs (see Levy et al. 2000). CYP2D6 accounts for the hepatic metabolism
of about 30% of clinically used drugs, including antiarrhythmic agents,
antihypertensives, β-blockers, monoamine oxidase inhibitors, morphine derivatives,
antipsychotics, and tricyclic antidepressants (see Gonzalez & Idle 1994).
In humans, CYP2D6 is polymorphic, and at least 70 CYP2D6 alleles have been
identified. Most of the known variant alleles are inactive, and produce the PM
phenotype (see Meyer & Zanger 1997; Idle 2000). The prevalence of the PM
phenotype shows marked ethnic differences, and it appears to be rare (∼1%) in most
Asian populations, common in whites (5%-10%), and varies in black populations of
African descent (0%-19%) (Bertilsson 1995; Tateishi et al. 1999). The molecular
genetic bases of the CYP2D6 polymorphism are now well established. Many types of
null mutations result in impaired CYP2D6 activity, and homozygosity is associated
with the PM phenotype, e.g., CYP2D6*3, *4, *5, and *6. Other variant alleles, such as
CYP2D6*9, *10, and *17, lead to an enzyme with reduced catalytic activity compared
to the wild-type allele (CYP2D6*1) (Johansson et al. 1994; Oscarson et al. 1997;
Tateishi et al. 1999).
Bufuralol and dextromethorphan have been used as in vitro probe substrates of
CYP2D6 (Schmid et al. 1985; Yamazaki et al. 1994). Inhibitors of CYP2D6 include
quinidine, fluoxetine, paroxetine, perphenazine, terbinafine and ticlopidine (see
Venkatakrishnan et al. 2001). Among these inhibitors, only quinidine has been widely
used as a potent and selective probe inhibitor in in vitro studies (Ki ∼ 0.06 µM)
(Bourrie et al. 1996) (Table 1). In contrast to most other hepatic CYP enzymes
involving in human drug metabolism, CYP2D6 seems not to be inducible (see Levy et
al. 2000).
1.2.6 CYP2E1 enzyme
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CYP2E1 constitutes approximately 6% of the total hepatic CYP enzymes and is
present in several extrahepatic tissues, including the lungs, kidneys, nasal mucosa,
bone marrow, and the white cell fraction of peripheral blood (Ding et al. 1986; 1990;
Song et al. 1990). Several factors including obesity and fasting can modulate human
CYP2E1 activity (O'Shea et al. 1994; Girre et al. 1994; Zand et al. 1993). In addition,
ethanol is an inhibitor of CYP2E1 after transient use and an inducer after chronic use
(Niemela et al. 2000). Isoniazid and imidazole can increase the translation efficiency
and affect CYP2E1 enzyme stabilisation (Park et al. 1993; Eliasson et al. 1990).
CYP2E1 is involved in the metabolic activation of many low molecular weight toxins
and carcinogens, including N-nitrosamines in tobacco smoke, benzene, ethanol, and a
number of drugs such as chlorzoxazone, acetaminophen, dapsone, aniline, and
fluorinated general anesthetics (Yamazaki et al. 1992).
CYP2E1 is also polymorphically expressed with up to 20-fold interindividul variation
among individuals (Shimada et al. 1994). Several genetic polymorphisms have been
identified in the CYP2E1 gene (Uematsu et al. 1991; Hu et al. 1997; McCarver et al.
1998; Fairbrother et al. 1998), and controversial frequencies of the polymorphisms
according to the racial/geographic characteristics of the study population have been
described (see Rodrigues 2002). In general, CYP2E1 activity, as measured both in
vitro and in vivo by the 6-hydroxylation of chlorzoxazone, does not appear to be under
genetic regulation by the known allelic variants (Lucas et al. 1995, Kim et al. 1996;
Fairbrother et al. 1998; Carriere et al. 1996; Powell et al. 1998). For example, the
difference of chlorzoxazone's oral clearance was less than 2-fold between the
homozygous wild-type individuals (c1/c1) and the variant c2 alleles (Marchand et al.
1999).
Chlorzoxazone has been used both in vivo and in vitro as a probe substrate of CYP2E1
(Peter et al. 1990). Disulfiram inhibits CYP2E1 activity, but it is also an almost
equally potent inhibitor of CYP2A6 (Guengerich et al. 1991). Diethyldithiocarbamate
(DDC), which is a mechanism-based inhibitor of CYP2E1, and pyridine have been
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used as useful in vitro tools for evaluation of the CYP2E1-mediated reactions
(Hargreaves et al. 1994; Newton et al. 1995) (Table 1).
1.2.7 CYP3A enzymes
CYP3A enzymes are the most abundant CYP enzymes, comprising approximately 30-
40% of the total hepatic CYP content (Shimada et al. 1994). CYP3A enzymes are
involved in the metabolism of most clinically used drugs (40%-50%) in humans. The
CYP3A subfamily contains 3 functional proteins: CYP3A4, CYP3A5 and CYP3A7
(Nelson et al. 1996).
1.2.7.1 CYP3A4 enzyme
CYP3A4 is the most abundantly CYP expressed in the human liver and intestine (see
Guengerich 1999), and its activity can be induced by rifampin, barbiturates,
carbamazepine, nevirapine, and dexamethasone in vivo and in vitro (Bertilsson et al.
1997; Goodwin et al. 1999). CYP3A4 plays a significant role in the metabolism of
almost half of the commonly used drugs, including nifedipine, felodipine,
cyclosporine, erythromycin, midazolam, alprazolam, triazolam, lovastatin, simvastatin,
terfenadine, verapamil, tacrolimus, diltiazem, cicapride, terstosterone, and HIV-
protease inhibitors (see Thummel et al. 1998; Rodrigues 2002).
CYP3A4 activity shows large interindividual variability (up to 40-fold in hepatic
microsomes), it is affected by genetic and environmental factors (Shimada et al. 1994).
In some studies, several genetic polymorphisms in the CYP3A gene were found using
restriction fragment length polymorphisms detected by Southern analysis, but none of
these was associated with the level of nifedipine oxidation activity among various liver
samples (Beaune et al. 1986; Bork et al. 1989).
There is considerable evidence for CYP3A4 behaviour allosterically, possibly due to
the simultaneous binding of two or more substrate molecules to its active site (Schwab
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et al. 1988; Shou et al. 1994; Ueng et al. 1997; Korzekwa et al. 1998). Such binding
can lead to atypical enzyme kinetics and inconsistent drug-drug interactions (Ekins et
al. 1998; Korzekwa et al. 1998). Therefore, it was recently recommended that at least
two chemically unrelated CYP3A4 substrates, such as midazolam and testosterone,
should be used as probe substrates in in vitro studies (see Tucker et al. 2001).
A number of drugs and foreign chemicals are clinically significant inhibitors of
CYP3A4 such as ketoconazole (Ki ∼ 15 nM), itraconazole (Ki ∼ 270 nM),
clarithromycin (Ki 10 ∼ 28 µM), erythromycin (Ki 13 ∼ 194 µM), fluconazole (Ki 1.3 ∼
63 µM), fluvoxamine (Ki = 5.6 µM), fluoxetine (Ki 7.1 ∼ 66 µM), cimetidine (Ki 36 ∼
268 µM), delavirdine (Ki = 22 µM), grapefruit juice and calcium antagonists (see
Thummel et al. 1998; Guengerich 1999; Levy et al. 2000). Troleandomycin has been
characterized as a selectively mechanism-based inhibitor of CYP3A4 in vitro (Chang
et al. 1994; Newton et al. 1995). Ketoconazole is also a potent and selective inhibitor
of CYP3A4 in vitro and in vivo with low concentrations (preferably 1 µM or lower)
(Newton et al. 1995; Bourrie et al. 1996) (Table 1).
1.2.7.2 CYP3A5 enzyme
CYP3A5 is 83% homologous to CYP3A4, but it is expressed at a much lower lever
than CYP3A4 in the liver (10-30% of CYP3A4) (see Thummel et al. 1998; Levy et al.
2000). CYP3A5 is polymorphically expressed in 30% of individuals, and it is
predominantly expressed in the kidney in most individuals (Schuetz et al. 1989;
Thummel et al. 1998). Also, CYP3A5 is expressed in a limited number of fetal livers
(Hakkola et al. 2001). CYP3A5 can be induced by rifampicin and phenobarbital in
hepatocyte cultures (Hukkanen et al. 2000; Asghar et al. 2002). CYP3A5 has been
shown to be capable of metabolising most substrates of CYP3A4 (Wrighton et al.
1989; 1990). However, because of its lower expression level, the role of CYP3A5 in
hepatic drug clearance has generally been regarded to be significantly smaller than that
of CYP3A4, although in certain extrahepatic organs, CYP3A5 may contribute
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significantly to the metabolism of some substrates, such as midazolam and endobiotics
(Levy et al. 2000).
Table 1 The marker reactions and respective chemical inhibitors of the major CYP forms in
man (modified from Pelkonen et al. 1998 and Rodrigues 2002)
CYP forms Marker reactions Selective inhibitors
CYP1A2 Phenacetin O-deethylation
Caffeine N3-demethylation
Ethoxyresorufin O-deethylation
Furafylline
CYP2A6 Coumarin 7-hydroxylation 8-Methoxypsoralen
CYP2B6 S-Mephenytoin N-demethylation Not available
CYP2C8 Paclitaxel 6α-hydroxylation Quercetin (not fully selective)
CYP2C9 Tolbutamide hydroxylation
Diclofenac 4′-hydroxylation
S-Warfarin 7-hydroxylation
Sulfaphenazole
CYP2C19 S-Mephenytoin 4′-hydroxylation Omeprazole
CYP2D6 Bufuralol 1′-hydroxylation
Debrisoquine 4-hydroxylation
Dextromethorphan O-demethylation
Quinidine
CYP2E1 Chlorzoxazone 6-hydroxylation Diethyldithiocarbamate (DDC)
CYP3A Midazolam 1′-hydroxylation
Testosterone 6β-hydroxylation
Triazolam 1′-hydroxylation
Erythromycin N-demethylation
Troleandomycin (TAO)
Ketoconazole
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1.2.7 CYP3A7 enzyme
CYP3A7 is the major CYP form detected in human embryonic, fetal and newborn
liver (de Wildt et al. 1999; Hakkola et al. 2001). It may also be selectively expressed
in adult livers at lower levels than CYP3A4 and CYP3A5 (Schuetz et al. 1994). The
role of CYP3A7 in drug metabolism is unclear.
2. Enzyme kinetics in drug metabolism
In vitro characterization of drug biotransformation generally begins with an enzyme
kinetics analysis of metabolite formation rate using human liver microsomes. A typical
enzyme kinetic analysis involving a mathematical description of reduced nicotinamide
adenine dinucleotide phosphate (NADPH)-dependent biotransformation rate as a
function of substrate concentration is based on the core assumptions that substrate
consumption is minimal (typically less than 5%), and that product formation rate is
linearly related to microsomal protein concentration and duration of incubation (Segel
1975). Normally, if the conversion of substrate to product is catalyzed by a single
enzyme, the enzyme kinetics can be well described by a Michaelis-Menten (MM)
equation (one-enzyme model) as follows (Segel 1975; Schmider et al. 1996):
V0 = Vmax ⋅ S / (Km + S) (1)
where V0 is the rate of product formation (or substrate disappearance), S is the
substrate concentration, Vmax is the maximal velocity of the reaction, and Km is the
MM constant representing the concentration of substrate that results in half-maximal
velocity.
Two or more CYP forms with distinct affinities may catalyze a given drug
biotransformation. In such cases, the relationship between V0 and S is biphasic, and
may be described by a high-affinity and a low-affinity component using a two enzyme
MM model (Schmider et al. 1996):
V0 = Vmax1 ⋅ S / (Km1 + S) + Vmax2 ⋅ S / (Km2 + S) (2)
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Some CYP enzymes (CYP2B6 and CYP3A4) have been shown to exhibit kinetics
consistent with allosteric interaction of the substrate with the enzyme, which is also
known as substrate activation (Ueng et al. 1997; Harlow & Halpert 1998; Shou et al.
1999). These result in an S-shaped substrate versus rate curve and a ''hook''-shaped
Eadie-Hofstee plot (see Rodrigues 2002). When allosteric interactions are observed,
the Hill equation can be used to calculate kinetic constants (Clarke 1998):
V0 = Vmax ⋅ Sn / (S50n + Sn)
where n is the Hill coefficient for cooperative substrate binding, S50 is the substrate
concentration at which half the maximal rate (Vmax) is attained.
Another kinetic profile, substrate inhibition, occurs when an increase in substrate
concentration beyond a certain value (usually greater than Km) results in a decrease in
the rate of metabolism (Haehner et al. 1996; Spracklin et al. 1997; Korzekwa et al.
1998). Although the mechanism of substrate inhibition has yet to be fully determined,
it has been described by a two-site model in which one binding site is productive,
whereas the other site is inhibitory and operable at high substrate concentrations,
resulting in decreased velocity with increasing concentrations (Shou et al. 2001;
Hutzler & Tracy 2002). In general, the magnitude of the inhibition of substrate
inhibition is dependent upon the structure and concentration of the substrate, the
reaction type, and CYP form examined. In most cases, substrate inhibition behaves as
a partial inhibition because the inhibition of CYP does not approach zero even at very
high substrate concentrations (Lin et al. 2001).
3. Mechanism of drug-drug interactions involving CYP enzymes
3.1 Inhibition of CYP enzymes
Inhibition of CYP enzymes is the most common cause of metabolism based drug-drug
interactions. The inhibition of CYP enzymes is of clinical importance for both
therapeutic and toxicological reasons. The mechanisms of CYP inhibition can be
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categorized into reversible inhibition and mechanism-based inhibition (see Lin & Lu
1998; 2001; Levy et al. 2000).
3.1.1 Reversible inhibition
Reversible inhibition is the most common type of enzyme inhibition. Reversible
inhibition is transient and reversible, and the normal functions of CYPs continue after
the inhibitor has been eliminated from the body (see Lin & Lu 2001). Reversible
inhibition can be further classified into competitive, uncompetitive, mixed-type and
non-competitive inhibition (see Rodrigues et al 2002). Competitive inhibition is when
the binding of an inhibitor to an enzyme prevents a further binding of a substrate to the
active sites of the enzyme. In uncompetitive inhibition, an inhibitor does not bind to
the free enzyme, but binds to the enzyme-substrate complex, resulting in a
nonproductive enzyme-substrate-inhibitor complex. Mixed-type inhibition is when an
inhibitor binds either to the free enzyme or to the enzyme-substrate complex (see Lin
& Lu 2001; Rodrigues 2002). In the case of noncompetitive inhibition, an inhibitor
binds to a nonactive binding site of the enzyme, and the binding has no effect on the
binding of substrate, but the enzyme-substrate-inhibitor complex is nonproductive.
Noncompetitive inhibition is a specific case of mixed-type inhibition. Mathematically,
the velocity of an enzymatic reaction in the presence of an inhibitor (Vi), can be
described by the following equations (3), (4), (5) and (6) for competitive,
uncompetitive, mixed-type and non-competitive inhibition, respectively (Segel 1975)
(Table 2) (Fig 1).
Vi = Vmax ⋅ S / [ Km (1 + I / Ki) + S ] (3)
Vi = Vmax ⋅ S / [ Km + S (1 + I / Ki) ] (4)
Vi = Vmax ⋅ S / [ Km (1 + I / Ki) + S (1 + I / αKi) ] (5)
Vi = Vmax ⋅ S / [ Km (1 + I / Ki) + S (1 + I / Ki) ] (6)
where Ki is the inhibition constant, (I) is the inhibitor concentration, and α is the factor
by which Km changes when an inhibitor occupies the enzyme.
3.1.2 Mechanism-based inhibition
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Mechanism-based inhibition can be mediated by covalent modification of a pyrrole
nitrogen in the prosthetic heme group of CYP or by direct modification of the heme
moiety or the apoprotein (Halpert 1995). The mode of inhibition is highly specific
because the inhibitor must both bind to and be metabolised by the enzyme (Lehman-
Mckeeman et al. 1997). The inhibitory effect of mechanism-based inhibition is
terminated by enzyme resynthesis rather than inhibitor washout (Mayhew et al. 2000).
One mode of mechanism-based inhibition is the formation of metabolite intermediate
(MI) complexes. Compounds forming MI complexes can be catalytically oxidized to
intermediate or product metabolites that uncovalently bind to the prosthetic heme of
the CYP. In the case of MI complexation, the CYP activity can be restored under
nonphysiological experimental conditions e.g. using potassium ferricyanide or by the
in vitro dialysis method (Regal et al. 2000; Ma et al. 2000). However, in real in vivo
situations, the MI complexes are so stable that resynthesis of new enzyme is the only
means by which the enzyme activity can be restored (Mayhew et al. 2000). A classic
example of the MI complexation is the inhibition of CYP3A4 by troleandomycin
(Newton et al. 1995).
Another mode of mechanism-based inhibition is the so-called enzyme inactivation (or
suicide inhibition). Suicide inhibition results from covalent binding of reactive
intermediates to the heme and /or protein of CYP (see Lin & Lu 1997; Levy et al
2000). Typical examples of suicide inhibition are inactivation of CYP1A2 by
furafylline, and inactivation of CYP3A4 by delavirdine (Kunze & Trager 1993;
Voorman et al. 1998).
The most important phenomena of mechanism-based inhibition are time-,
concentration-, and NADPH-dependent loss of the enzyme activity (see Lin et al.
1995; Lin & Lu 1997). In vivo, the inhibitory effect of a mechanistic inactivator is
thought to be more prominent after repeated dosing and last longer than that of a
reversible inhibitor (see Lin & Lu 1998). Many drugs have been identified as
mechanism-based inactivators in vitro, and have considerable form specificity. These
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inhibitors include furafylline (CYP1A2 inhibitor; KI = 23 µM, Kinact = 0.87 min-1)
(Kunze & Trager 1993), menthofuran (CYP2A6 inhibitor; KI = 2.5 µM, Kinact = 0.22
min-1 in human liver microsomes, and KI = 0.84 µM, Kinact = 0.25 min-1 in purified
expressed CYP2A6) (Khojasteh-Bakht et al. 1998), tienilic acid (CYP2C9 inhibitor; KI
= 4.3 µM, Kinact = 0.21 min-1) (Lopez-Garcia et al. 1994; Jean et al. 1996), halothane
(CYP2E1 inhibitor; data for KI and Kinact not available) (Madan & Parkinson 1996),
gestodene (CYP3A4 inhibitor; KI = 46 µM, Kinact = 0.39 min-1) and delavirdine
(CYP3A4 inhibitor; KI = 22 µM, Kinact = 0.59 min-1) (Guengerich 1990; Voorman et
al. 1998).
3.2 Induction of CYP enzymes
Enzyme induction is less frequently encountered and its development is a slower
process in clinical practice than enzyme inhibition. Enzyme induction can occur by
means of ligand stabilisation of the enzyme (ethanol-type induction) or by increased
enzyme synthesis involving intracellular receptors such as the aryl hydrocarbon (Ah)
receptor, the peroxisome proliferator activated receptor (PPAR), the constitutive
androstane receptor (CAR, Phenobarbital induction) and the pregnane X receptor
(PXR, rifampicin induction) (see Pelkonen et al. 1998; Fuhr 2000). Normally, enzyme
induction may attenuate therapeutic efficacy as a result of a decrease in plasma active
parent drug concentrations (Park et al. 1996). Human CYP1A1/2, CYP2A6, CYP2C9,
CYP2C19, CYP2E1, and CYP3A4 are known to be inducible (Ronis et al. 1999).
Many drugs including rifampicin, dexamethasone, and anticonvulsants (such as
phenytoin, carbamazepine, phenobarbital and primidone) are important inducers of
CYP3A4 and some other forms (see Pelkonen et al. 1998).
Ethanol-type induction appears to be limited to the target enzyme CYP2E1. Four
major mechanisms have been proposed for the regulation of CYP2E1 by xenobiotics
and these include transcriptional activation occurring in the nucleus, stabilization of
2E1 transcripts in the cytosol, enhanced polyribosomal messenger RNA translational
efficiency, and protein stabilization occurring in the endoplasmic reticulum (Koop et
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al. 1990). Any or all of these mechanisms may cause enhanced 2E1 expression when a
cell is targeted by a drug or chemical. The xenobiotic inducers of CYP2E1 include
ethanol, isoniazid, imidazole, pyridine, pyrazole, halogenated hydrocarbons, and
acetone (Lieber 1997; Raucy et al. 1993; Koop et al. 1990).
The induction of CYP1A1 is regulated by the ligand binding of polycyclic aromatic
hydrocarbons, which are found in tobacco smoke, to the cytosolic Ah receptor to
increased protein synthesis, and to the initiation of transcriptional activation of the
CYP1A1 gene (Okey 1990; Porter & Coon 1991). However, CYP1A induced by
omeprazole is not a direct ligand for the Ah receptor, but the induction process is
mediated by enhanced translocation of the Ah receptor to the nuclei and binding to the
regulatory elements upstream of the CYP1A coding genes (Quattrochi & Tukey 1993).
In contrast to the induction of CYP1A genes, the mechanism of the induction
involving CAR, PXR and PPAR, which belong to the nuclear receptor/steroid receptor
superfamily, is via foreign chemical inducers binding to receptors (CAR, PXR and
PPAR) and transcription factors to induce CYP gene expression (see Waxman 1999;
Fuhr 2000). For example, phenobarbital and many other phenobarbital-like lipophilic
chemicals induction of CYP2B gene via CAR, PXR activates CYP3A genes in
response to diverse chemicals including certain natural and synthetic steroids, and
PPAR mediates the induction of the fatty acid hydroxylases of the CYP4A family by
many acidic chemicals classified as non-genotoxic carcinogens and peroxisome
proliferators (Bertilsson et al. 1998; Issemann & Green 1990; Gonzalez et al. 1998).
4. In vitro systems in evaluating and predicting metabolic clearance and drug-
drug interactions
In vitro systems can be placed into two broad categories. The first type of in vitro
systems is the enzyme-based systems, which include liver microsomes, and cDNA-
expressed enzymes. In addition, purified P450s reconstituted with cytochrome P450
reductases, b5, and other cofactors also belong to this system. However, due to the
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extremely difficuly for procurement, the purified enzymes are rarely used in practice,
and largely been replaced by cDNA-expressed CYP enzymes. The second and more
complex system is the cell-based systems, which include the hepatocytes and liver
slices (see Wrighton et al. 1993; Levy et al. 2000).
4.1. Enzyme-based systems
4.1.1 Human liver microsomes
The microsomal cellular fraction is the postmitochondrial supernatant that is separated
by centrifugation at 100,000 g to 250,000 g for 60 to 120 minutes and it consists of
''pinched-off'' closed vesicles of fragments of endoplasmic reticular membrane (Lake
1987). Microsomes prepared from human livers are the primary tools used for in vitro
studies of metabolic-based drug-drug interactions and CYP-catalyzed metabolite
formation. The systems have several advantages over other in vitro systems. As the
ratio of NADPH-cytochrome P450 reductase to CYP in human liver microsomes and
the amount of cytochrome b5 and the type of lipids are the same as those in the intact
liver, the metabolism data obtained using human liver microsomes appear to have
greater relevance to the in vivo situation than data obtained through the use of isolated
enzymes (see Lin & Lu 1997; Levy et al. 2000). In addition, the relative importance of
different routes of metabolism obtained following liver microsomal incubations more
closely approximates those observed in vivo than the information obtained by isolated
enzyme preparations (see Levy et al. 2000). Furthermore, the microsomes are easy to
obtain and store, the enzymes activities can be kept in crystal (frozen) forms for many
years, and the experimental methods and the mathematical models used in human liver
microsomal studies are well established (Clarke 1998; von Moltke et al. 1998).
Despite its prominent advantages, the microsomal system has its own drawbacks. For
example, the microsomes contain only phase I drug metabolising enzymes and uridine
diphosphate-glucuronosyl transferases, thus the metabolic environment and cofactors
are different from those in vivo (see Levy et al. 2000). In addition, the in vitro
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incubation conditions used such as the ionic strength, pH value of the incubation
medium and the effect of organic solvents used can affect the outcomes of microsomal
studies (see Venkatakrishnan et al. 2001).
4.1.2 cDNA-expressed enzymes
Advances in molecular biology have resulted in that the recombinant DNAs (cDNAs)
encoding the drug-metabolising CYP enzymes can be isolated and transfected into
host cells, such as bacteria, yeast, insect, human and other mammalian cells, to express
the CYP protein (Ekins et al. 2000). The generally used cDNA-expressed CYP forms
express only a single enzyme activity, thus they are very useful in studies of CYP
form-specific drug metabolism and interactions (see Levy et al. 2000). In addition, the
cDNA-expressed enzymes are commercially available and easy-to-use in in vitro
studies. However, the amounts of individual enzymes and cofactors in expressed
enzymes are different from those in human liver. Therefore, the contribution of an
enzyme to a specific metabolic route may not be as significant as it seems on the basis
of cDNA-expressed enzymes (see Levy et al. 2000). For example, the variable
expression of cytochrome b5 and/or NADPH-cytochrome P450 reductase can affect
the turnover number (Vmax) for a given enzyme (Shaw et al. 1997; Yamazaki et al.
1999), although the ''affinity'' (Km) of CYP enzymes toward marker substrates is
generally comparable between recombinant enzymes and human liver microsomes
(McGinnity et al. 1999). In addition, transfection into nonhuman, nonhepatic celluar
hosts may result in the Km and Vmax values of the expressed enzymes substantially
differing from those observed in the native enzymes (Shaw et al. 1997).
4.2 Cell-based systems
Cell-based systems include human liver slices and hepatocyte systems, which are
useful in vitro tools for drug metabolism and interaction studies. Both systems retain
the physiological conditions of enzymes and co-factors of both phase I and phase II
reactions, and therefore, they can well simulate the in vivo situation (see Lin & Lu
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1997). Furthermore, these systems can also be used for studying xenobiotic-mediated
induction of drug-metabolising enzymes (see Venkatakrishnan et al. 2001). However,
operation with cell-based systems needs fresh tissues and requires specific techniques
and established procedures. In addition, kinetic parameters obtained from liver slices
may be different from those obtained in hepatocytes or liver microsomes, since the
distribution equilibrium of the drug or compound may not be well achieved between
all the cells within the liver slice and the incubation media (see Lin & Lu 1997).
Moreover, the results obtained from hepatocytes should be interpreted with caution,
because the enzyme activities decline spontaneously during hepatocyte isolation or
culture (see Skett et al. 1995; Ekins et al. 2000; Pelkonen et al. 2001). To date, the
specific CYP forms sensitive to the decline has not been identified.
Because each approach mentioned above has its own advantages and limitations, a
combination of several approaches undoubtedly provides the most convincing
evidence for drug metabolism and interactions studies.
5. In vitro approaches in the prediction of metabolic clearance
5.1 Intrinsic clearance
Intrinsic clearance (Clint) is the cornerstone for extrapolation of in vitro data to the in
vivo situation (see Pelkonen et al. 1998). Clint is a direct measure of enzyme activity
toward a drug and is not influenced by other determinants such as hepatic blood flow
or drug binding within the blood matrix. Clint acts as a proportional constant between
rate of drug metabolism and drug concentration around the metabolic enzyme site
(CE). If the process is consistent with a MM model, and if CE is less than 10% of the
Km, Clint is equal to the Vmax/Km ratio (see Houston 1994) i.e.:
Clint = Vmax / Km (7)
In the cases of two-enzyme kinetics, the net intrinsic clearance is the sum of the low-
and the high-affinity clearance (see Thummel et al. 1997; Venkatakrishnan et al.
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2001):
Clint = Vmax1 / Km1 + Vmax2 / Km2 (8)
5.2 Prediction of in vivo metabolic clearance based on in vitro data
In many cases, in vivo metabolic clearance (Clmet) can be predicted using in vitro drug
metabolism data based on the assumption that only the unbound drug can cross
through the membranes, and that there is a homogenous distribution of enzymes within
the liver (see Houston 1994; Iwatsubo et al. 1997; Lin & Lu 2001). Based on these
assumptions, the hepatic clearance (Clh) can be predicted in vitro using the well-stirred
model (see Houston 1994; Ito et al. 2000a):
Clh = Q ⋅ E = Q ⋅ fu ⋅ Clint / (Q +fu Clint) (9)
or the parallel-tube model:
Clh = Q ⋅ E = Q (1 − e−fu ⋅ Clint/ Q) (10)
where Q is the hepatic blood flow (20 ml/min/kg) (Lin & Lu 1997), E is the hepatic
extraction ratio calculated as Clh/Q, Clint is the in vivo intrinsic clearance, and fu is the
unbound fraction of a drug in the blood.
Kinetically, drugs can be classified as low- (enzyme limited, E < 0.5, such as
ketoconazole and ritonavir) or high-clearance (flow limited, E > 0.9, such as indinavir,
saquinavir, and nisoldipine) compounds (see Wilkinson 1987). When the Clint of a
drug is very small relative to the hepatic blood flow (Q >> fu ⋅ Clint), the hepatic
clearance is low and Clh is directly related to fu and Clint, i.e. Clh ≈ fu ⋅ Clint. Thus, a
decrease in the Clint caused by inhibition will result in an almost proportional change in
the clearance of low-clearance drugs. However, if the Clint is high (fu ⋅ Clint >> Q), then
the hepatic clearance is limited by the hepatic blood flow, i.e. Clh ≈ Q, thus, a decrease
in the Clint caused by inhibition has little effect on the Clh of high-clearance drugs (see
Lin 1998; Rodrigues 2002).
5.3 Considerations in the prediction of metabolic clearance
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Nonspecific substrate binding to microsomal matrices may influence the estimation of
Clint in vitro. As microsomal binding can reduce enzyme-available substrate
concentrations and increase the estimated apparent Km of the process, yielding an
underestimation of the Vmax/Km ratio (see Venkatakrishnan et al. 2000; Mclure et al.
2000). Thus, the use of free in vitro intrinsic clearance (that is, Clint divided by the free
fraction in the incubation matrix), rather than total intrinsic clearance, improves a
prediction of in vivo pharmacokinetic clearance of extensively bound drugs (Obach
1997; 1999). This is more suitable for the lipophilic basic drugs, such as amiodarone,
desipramine, imipramine, nortriptyline, amitriptyline, and propranolol that are
extensively bound to microsomal matrices (Carlile et al. 1999; Obach 1999; Mclure et
al. 2000).
A change in the hepatic blood flow will result in a substantial change in the in vivo
hepatic clearance of a high-clearance (flow-limited) drug because the hepatic clearance
of a high-clearance drug is highly dependent on the hepatic blood flow (Lin & Lu
1998). But for a low-clearance (enzyme-limited) drug, a change in the hepatic blood
flow will have little effect on its hepatic clearance (see Bertz & Granneman 1997).
The addition of albumin and cytosol to the incubation medium may also affect the in
vitro-in vivo extrapolation. It has been noted that the addition of albumin and cytosol
to microsomal incubations may substantially change the enzyme kinetic estimates of
the substrates of CYP2C9 (Ludden et al. 1997; Carlile et al. 1999). For example, the
addition of bovine serum albumin to microsomal incubation media has decreased the
Km estimates and increased Clint for phenytoin p-hydroxylation and tolbutamide
hydroxylation, reactions mainly catalysed by CYP2C9, yielding predicted clearance
values more comparable with the in vivo values (Ludden et al. 1997; Carlile et al.
1999). In addition, phenytoin and tolbutamide oxidation in human liver microsomes
was substantially promoted by the addition of liver cytosol (Komastu et al. 2000a).
Both albumin and cytosolic components are probably present at the metabolic enzyme
site in vivo (Shroyer & Nakane 1987; Komastu et al. 2000a). Although several in vitro
studies have shown good agreement between the actual in vivo clearance and the
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predicted in vivo clearance based on in vitro kinetic estimates in the presence of
albumin and cytosol (Ludden et al. 1997; Carlile et al. 1999), testing for the utility of
albumin and cytosol in the prediction of in vivo clearance requires further
extrapolation with other substrates and other CYP enzymes.
6. In vitro approaches in the prediction of drug-drug interactions
6.1 Determination of in vitro potency of inhibition
In the case of reversible inhibition, the in vitro inhibitory potency of a given
compound is quantified by determination of its IC50 and Ki values (Newton et al.
1995). The IC50 value is defined as a concentration of inhibitor that causes 50%
inhibition of an original enzyme activity. The IC50 value can be determined by
analyzing the relationship between inhibitor concentration and decrement in reaction
velocity performed at a fixed substrate concentration (around Km) (see Rodrigues
2002). The IC50 value is quite useful when comparing the inhibitory potencies of
different candidate inhibitors of the same chemical class, but without any knowledge
of the biochemical mechanism of inhibition (von Moltke et al. 1998). However, IC50
values have their own important limitations in the context of in vitro-in vivo scaling
(Brosen et al. 1993). IC50 value is dependent on the type of inhibitory mechanism. For
example, IC50 is equal to the inhibition constant (Ki) only when the biochemical
mechanism is noncompetitive or the substrate concentration used is much less than K m
for competitive inhibition (Venkatakrishnan et al. 2001). If the substrate concentration
approaches or exceeds Km, the IC50 value exceeds the competitive Ki (von Moltke et
al. 1998). However, this limitation can be overcame by actual calculation of an in vitro
Ki value based on a methodology involving coincubating varying concentrations of
substrate with varying concentrations of a candidate chemical inhibitor.
Ki, which expresses or is related to the affinity of a compound to an enzyme, is one of
the key parameters for prediction of in vivo drug-drug interactions resulting from
metabolic inhibition. Ki can be estimated either graphically by using plotting methods
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or by nonliear regression analysis. The Dixon plot (Fig 2A) relies on a linearized form
of a nonlinear relationship of the inhibitor concentration versus the reciprocal of the
rate of metabolite formation (Segel 1975). The Lineweaver-Burk plot (the double
reciprocal plot), which relies on a linearized form of a nonlinear relationship of the
reciprocal of the rate of metabolite formation vs the reciprocal of the substrate
concentrations, is frequently used to identify the likely mechanism of the enzyme
inhibition. Secondary plot (Fig 2B), which relies on a linearized form of a nonlinear
relationship of slopes taken from the double reciprocal plots vs the inhibitor
concentrations, is another plotting method to estimate the Ki value (Segel 1975).
However, the most reliable and robust method for analyzing Ki is nonlinear regression
analysis, where all data are fit simultaneously to nonlinear inhibition models
[equations (3), (4), (5), and (6), see Review of the Literature, section 3.1.1] (Kakkar et
al. 1999; 2000; Cleland 1989).
In the case of mechanism-based inactivation, time-, concentration- and NADPH-
dependent loss of enzyme activity is an important consequence of the processes. The
important kinetic parameters for mechanism-based inactivation include the half-life of
enzyme inactivation (T1/2), the rate constant of inactivation (Kinact) and the
concentration of inactivator that produces half the maximal rate of inactivation (KI).
After preincubation of the microsomes with NADPH for an appropriate time in the
presence or absence of various concentrations of an inhibitor, the T1/2 and the apparent
inactivation rate constant (Kobs) can be estimated from linear regression analysis of the
natural logarithm of residual enzyme activity against the preincubation time (Fig 3A).
The KI and Kinact can be calculated from a double-reciprocal plot of the inactivation
rate constant (Kobs) versus inhibitor concentration (Fig 3B). The intercept on the
ordinate gives 1/Kinact. If the line is extrapolated to the abscissa, the intercept gives -
1/KI (Kent et al. 1999; Koenigs et al. 1997). In addition to the linearized plots, KI and
Kinact can also be estimated by fitting data to the following equation using nonlinear
regression analysis (see Lin & Lu 1998):
T1/2 = 0.693 (1 + KI /I)/Kinact (11)
where I is the concentration of a mechanism-based inactivator.
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6.2 Prediction of metabolic inhibition using an in vitro-in vivo scaling model
Because of limitations of in vivo studies and problems in extrapolating the results of
animal studies to humans, in vitro systems using human tissues have become widely
used tools to predict potential drug-drug interactions in humans. The benefit of these
studies is that in vitro data concerning the potential for drug-drug interactions can be
obtained early in the drug development phase, thereby helping researchers to focus on
in vivo interaction studies and the prediction of pharmacokinetic variability (see Levy
et al. 2000; Lin & Lu 2001).
In vitro-in vivo scaling models of pharmacokinetic interactions involving metabolic
inhibition are based on the hypothesis that the fractional decrement in reaction velocity
(FDV) in vitro in principle corresponds to the fractional decrement of clearance
(FDCL) in vivo (von Moltke et al. 1995b; 1998). FDCL is based on the clearance of
the substrate, measured with no inhibitor present, and coadministration of the inhibitor.
FDV is related to the V0 (velocity in the absence of inhibitor) and Vi (velocity in the
presence of inhibitor) (von Moltke et al. 1995b; 1998). Using competitive inhibition as
an example, the V0 and Vi can be expressed using equations (1) and (3) (see Review of
the Literature, section 2 and 3.1.1), and consequently, the FDCL can be calculated by
the following equation:
FDCL = FDV = (V0 - Vi) / V0 = I / Ki [1+ I / Ki + S / Km] (12)
Thus, the potency of inhibition is dependent on both the ratios of (I/Ki) and (S/Km). If
the substrate concentration is far below its Km (S << Km), the S/Km ratio approaches
zero and the equation (12) becomes:
FDCL = FDV = I / (I + Ki).
In the case of noncompetitive inhibition, FDCL = I / (I + Ki) regardless of the values
of S and Km (see Lin & Lu 1997; 1998; Von Moltke et al. 1998; Venkatakrishnan et al.
2001).
Accordingly, drug-drug interactions based on inhibition of hepatic metabolism (i) can
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be roughly predicted by the Ki value and the unbound concentration of inhibitor (I)
around the metabolic enzyme site in the liver using the following equation regardless
of the type of inhibition (see von Moltke et al. 1998; Rodrigues 2002) (Table 2).
i = I / (I + Ki) (13)
It should be kept in mind that if S approaches Km, this equation (13) overestimates the
degree of inhibition.
Table 2 Enzyme kinetic equations and in vitro-in vivo scaling models for inhibition of CYP
enzymes (adopted from Rodrigues 2002)
Inhibition type Enzyme kinetic equation In vitro-in vivo extrapolation
No inhibition V0 = Vmax S/(Km + S) Not applicable
Competitive Vi = Vmax S/[Km (1 + I/Ki) + S] i = I/[(I + Ki (1 + S/Km)]
As S << Km, i = I/(I + Ki)
Noncompetitive Vi = Vmax S/[Km (1 + I/Ki) + (1 +
I/Ki) S]
i = I/(I + Ki)
Uncompetitive Vi = Vmax S/[Km + (1 + I/Ki) S] i = I/[(I + Ki (1 + Km /S)]
As S << Km, i → 0, as S→
Km, i becomes significant.
Mixed-type inhibition
(competitive-
noncompetitive)
Vi = Vmax S/[Km (1 + I/Ki) + (1 +
I/αKi) S]
As S << Km, i = I/(I + Ki)
V0: the initial rate of the reaction in the absence of inhibitor; Vi: the rate of the reaction in the
presence of inhibitor; S: the substrate concentration; I: the inhibitor concentration; Vmax and
Km: the apparent Michaelis-Menten kinetic constants; Ki: the inhibition constant; α: the factor
by which Km changes when an inhibitor occupies the enzyme; fractional inhibition (i) is the
predicted inhibition of CYP forms in vivo in the presence of an inhibitor.
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Although many drugs have been identified as mechanism-based inactivators in vitro,
the mechanisms involved are not always clear. Prediction of  in vivo situations based on
in vitro data is very complex, uncertain, and susceptible to many affecting factors
(Mayhew et al. 2000; Rodrigues 2002). For example, an inactivator can be released
from the enzyme through reversible binding, and the degradation rates of the enzymes
may be substantially affected by the inactivator (see Ito et al. 1998b; Lin & Lu 1998;
Mayhew et al. 2000). Consequently, the prediction of drug-drug interactions related to
mechanism-based inhibition is somewhat difficult and not straightforward, despite
some successful in vitro-in vivo extrapolations (Mayhew et al. 2000; Rodrigues 2002).
6.3 Factors to be considered in in vitro-in vivo extrapolation
In the aforementioned in vitro-in vivo scaling model, the real in vivo concentration of
an inhibitor around the enzyme is unknown. Based on a hypothesis stating that only
the unbound concentration in plasma is available for diffusion into intrahepatic sites,
the unbound plasma concentration of an inhibitor has been used to predict in vivo drug
interactions (see Ito et al. 1998b). However, this hypothesis is not suitable for many
lipophilic compounds, since the liver concentrations of these compounds may even
greatly exceed their total plasma concentrations, despite extensive plasma protein
binding (Bogeyevitch et al. 1987; Chou et al. 1993; Levine et al. 1994;
Rodrigues 2002). In such cases, successful prediction of in vivo drug-drug interactions
has been achieved by using the total plasma concentration of an inhibitor or
multiplying total plasma concentration by a liver/plasma partition ratio (von Moltke et
al. 1994a; 1994b; von Moltke et al. 1998).
In addition to the estimation of the inhibitor concentration (I), the estimation of the in
vitro Ki value is also very critical for the scaling process. Factors such as incubation
conditions, nonspecific binding to microsomal proteins, and the chemical inhibitors
used may affect the accuracy of the estimation of Ki (Obach 1997). Being a substrate
of certain microsomal enzymes or by binding extensively to the enzymes, an inhibitor
may be significantly depleted during the incubation. Thus, the Ki value of the inhibitor
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may be overestimated especially if a high microsomal protein concentration is used.
For example, the Ki value for ketoconazole-CYP3A4 (midazolam α-hydroxylation)
interactions in human liver microsomes was estimated to be about 8 µM using a 1.5
g/L microsomal protein concentration, whereas the Ki value was about 0.18 µM using
a 0.25 g/L microsomal protein concentration (Lampen et al. 1995; Wang et al. 1999).
Thus, a 6-fold increase in the microsomal protein concentration resulted in a 44-fold
increase in the estimated Ki value. As a result, it may be beneficial to run experiments
at the lowest possible protein concentration to help reduce the effects of nonspecific
binding.
Accumulation of potent inhibitory metabolites in the incubation medium may also
result in inaccurate estimation of Ki values. For example, N-desmethyl (Ki = 2 µM)
and N, N-didesmethyl (Ki = 0.1 µM) metabolites of diltiazem are more potent in
inhibiting CYP3A4-mediated testosterone 6β-hydroxylation than the parent drug (Ki =
60 µM) (Sutton et al. 1997).
The role of P-glycoprotein (P-gp) involved in the drug interactions has been
recognized. P-gp is not only overexpressed in the development of multidrug resistance
by tumour cells exposed to cancer chemotherapeutic agents (Gottesman et al. 1993),
but is also presents in normal tissues including the intestines, liver, kidneys and brain,
where it is considered to function as a drug efflux pump to reduce drug absorption, or
enhance drug excretion into bile and urine (Wandel et al. 2000). P-gp and CYP3A4 are
co-expressed in specific cell types, such as enterocytes and hepatocytes, and they also
share a large number of substrates and modulators (Wacher et al. 1995; Kim et al.
1998). Inhibition of P-gp produces an increase in drug absorption and a decrease in
hepatic and renal excretion of its substrates, resulting in elevated plasma and organ
drug levels, particularly in the brain (Schinkel et al. 1996).
The choice of the inhibitor concentrations used may also affect the in vivo result. For
example, ketoconazole, a very potent and relatively selective CYP3A4 inhibitor, can
inhibit the catalytic activity of all major CYP activities when used at very high
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concentrations (100 µM) (Newton et al. 1995). It is essential to consider other factors
such as the choice of the substrate concentrations and the extrahepatic drug
metabolism (especial for drug with substantial first-pass metabolism) when
extrapolating in vitro results to in vivo situations (see Hall et al. 1999; Schinkel et al.
1996).
Although in vitro studies can provide valuable information, quantitative prediction of
in vivo situations based on in vitro data can be foiled by numerous factors. Interpreting
in vitro results needs a good understanding of the underlying pharmacokinetic
principles, and mechanisms involved in drug interactions.
7. Clinical significance of drug-drug interactions involving CYP enzymes
In clinical practice, when two or more drugs are administered at the same or
overlapping times, there is always a concern for drug-drug interactions. Although
interactions can be pharmacokinetic or pharmacodynamic in nature, in many cases, the
interactions have a pharmacokinetic basis (see Guengerich 1997; Lin & Lu 1998).
There are many underlying mechanisms responsible for pharmacokinetic interactions
that can be understood in terms of alterations of CYP-catalyzed reactions. The major
reasons for drug-drug interactions involving CYP enzymes are induction, inhibition,
and possibly stimulation, with inhibition appearing to be the most important in terms
of known clinical problems (see Guengerich 1997; Lin & Lu 1998; Rodrigues 2002).
The inhibition of CYP enzymes can result in the undesirable elevation of plasma drug
concentrations, leading to toxicity or therapeutic failure (see Lin & Lu 1998). For
example, the concomitant use of terfenadine (metabolised entirely by CYP3A4) with
CYP3A4 inhibitors, including the azole antifungals (ketoconazole, itraconazole) and
macrolide antibiotics (erythromycin, clarithromycin, troleandromycin) can cause toxic
accumulation of terfenadine in plasma and prevent the formation of antihistamine
metabolite (Gillum et al. 1993; Guengerich 1997; Dresser et al. 2000; Rodrigues
2002). Coadministration of mibefradil (potent CYP3A4 inhibitor) with the substrates
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of CYP3A4 such as triazolam, terfenadine, cyclosporine A, and quinidine, can result in
the plasma concentrations of these drugs being substantially elevated by mibefradil,
resulting in significantly adverse reactions (Welker et al. 1998; Backman et al. 1999;
Wang et al. 1999; Ma et al. 2000). A good understanding of the underlying
mechanisms involving in such drug-drug interactions can avoid toxicity or therapeutic
failure by a corresponding reduction or increment of the therapeutic doses of a targeted
drug, or close monitoring of its plasma concentration whenever a precipitant
compound is added to the therapeutic regime.
8. Individual drugs studied
8.1 Valproic acid
Pharmacokinetics Valproic acid is a widely used anticonvulsant agent. Valproic acid
has been shown to be completely absorbed following oral administration (see Dollery
1999). Its time to peak plasma concentration (tmax) is 1-2 h and the elimination half-life
(t1/2) is 12 h (Klotz et al. 1977). After a 1000 mg single oral dose of valproic acid, its
peak plasma concentration (Cmax) ranged from 40 to 110 mg/l (240-662 µM) (Davis et
al. 1994). In patients with normal renal and hepatic functions, the binding of valproic
acid to plasma proteins (mainly albumin) is concentration-dependent (85%-94%) (see
Dollery 1999). It is thus estimated that the plasma-unbound valproic acid
concentration is normally lower than 15 mg/l (130 µM) after a usual therapeutic dose
of valproic acid. However, the free fraction of valproic acid increases nonlinearly
when its total plasma concentrations exceed 92 mg/l (550 µM) (Davis et al. 1994)
(Table 3).
Metabolism Valproic acid is eliminated via extensive hepatic metabolism to several
metabolites (Davis et al. 1994). Its major metabolic pathways are glucuronidation and
mitochondrial β-oxidation, while CYP-dependent oxidation is only a minor pathway
(Rettie et al. 1995) (Fig 4). The steady-state plasma concentrations of the metabolites
are at least 100-fold lower than those of the parent compound (Levy et al. 1990). Thus,
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it is unlikely that the metabolites would significantly alter CYP-dependent drug
metabolism in vivo. However, 4-ene-valproic acid, a minor metabolite whose
formation is mediated by CYP2C9 and CYP2A6 in vitro, is possibly involved in
valproic acid-mediated hepatotoxicity (Sadeque et al. 1997) (Table 3).
Drug-drug interactions Several drug-drug interactions between valproic acid and
CYP substrates have been reported. In one study, valproic acid at a serum
concentration of about 400 µM reduced the systemic clearance of unbound phenytoin
by 23% (Perucca et al. 1980). Valproic acid (500 mg, twice daily) increased the
maximum serum levels and the area under the curve (AUC) of amitriptyline by 19%
and 30%, respectively (Wong et al. 1996). In addition, valproic acid (250 mg, twice
daily) prolonged the t1/2 of phenobarbital from 96 to 142 h and decreased its metabolic
clearance from 3.3 to 2.0 mg/hr/kg (Patel et al. 1980). Furthermore, the concentrations
of unbound diazepam in serum were significantly increased and the clearance of
unbound diazepam was significantly reduced by valproic acid 1500 mg daily (Dhillon
et al. 1982). In vitro studies showed that 100 µM and 250 µM valproic acid had no
effect on CYP3A4-mediated cyclosporin oxidation and on the CYP2D6-mediated
hydroxylation of mexiletine (Broly et al. 1990; Pichard et al. 1990).
8.2 Gemfibrozil
Pharmacokinetics Gemfibrozil is a fibric acid derivative, which is used in the
treatment of patients with hypertriglyceridaemia and hypercholesterolaemia (Todd &
Ward 1988). Gemfibrozil is rapidly and completely absorbed following oral
administration. After the usual daily doses of gemfibrozil (600 mg b.i.d.), its Cmax is
about 30-60 mg/l (120-240 µM), and the average total plasma gemfibrozil
concentrations during the 12-h-dosing interval are about 5-23 mg/l (20-92 µM)
(Backman et al. 2000). Its tmax is 1 to 2 h and t1/2 is 1.5 h (Miller & Spence 1998).
Gemfibrozil is extensively bound to serum albumin (about 95%) (Miller & Spence
1998) (Table 3).
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Metabolism Gemfibrozil is metabolised to a number of compounds in man (see
Dollery 1999). About 48%-70% of the administered doses are excreted in the urine,
and the rest is excreted mainly as glucuronide conjugates of gemfibrozil and its
oxidised metabolites (Todd & Ward 1988; Parfitt 1999) (Table 3) (Fig 5).
Drug-drug interactions Gemfibrozil has been reported to enhance the anticoagulant
effect of warfarin, resulting in severe hypoprothrombinemia and bleeding (Ahmad
1990; Rindone & Keng 1998). In one case report, gemfibrozil has been reported to
interact with glyburide, resulting in hypoglycemia (Ahmad 1991). Gemfibrozil also
increased the AUC of glimepiride by 23%, and prolonged the t1/2 of glimepiride from
2.1 to 2.3 h (Niemi et al. 2001). In addition, it has been documented that a combined
therapy of gemfibrozil and statins such as atorvastatin, cerivastatin, lovastatin or
simvastatin can result in severe myopathy and rhabdomyolysis (Murdock et al. 1999).
Gemfibrozil-statins interactions may have a pharmacokinetic explanation, since
gemfibrozil has markedly increased the plasma concentrations of active simvastatin
acid and lovastatin acid, whereas it only slightly increased that of the parent
simvastatin and lovastatin (Backman et al. 2000; Kyrklund et al. 2001). In in vitro,
gemfibrozil has been confirmed not to be an inhibitor of CYP3A4 (Backman et al.
2000).
8.3 Isoniazid
Pharmacokinetics Isoniazid is widely used in the treatment and prophylaxis of
tuberculosis. It is rapidly and completely absorbed after oral administration. The Cmax
of isoniazid is 3-7 mg/l (22-50 µM) and is achieved 1-2 h after oral administration of a
normal therapeutic dose (300 mg/day) (see Dollery 1999). The t1/2 of isoniazid exhibits
a wide interindividual variability and is determined by the acetylator status. The t1/2 of
isoniazid is about 0.5-2 h in rapid acetylators, while it is about 2-6.5 h in slow
acetylators (Weber & Hein 1979). Isoniazid is probably not bound to an appreciable
extent to plasma proteins (Boxenbaum et al. 1975) (Table 3).
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Metabolism The major metabolic pathway of isoniazid in man is acetylation by a
cytosolic N-acetyltransferase (Weber & Hein 1979; Meyer & Zanger 1997) (Fig 4).
However, an in vitro study suggested that CYP enzymes might contribute to the
metabolism of isoniazid to isonicotinic acid and hydrazine, which constitute a small
fraction of the total metabolism of isoniazid (Ono et al. 1998). Isoniazid also
undergoes appreciable presystemic (first-pass) metabolism in the wall of the small
intestine and liver, and therefore its concentration in the plasma of rapid acetylators is
half of the concentration in slow acetylators after a normal therapeutic dose (300 mg)
of isoniazid (see Dollery 1999) (Table 3).
Drug-drug interactions In humans, isoniazid (300-600 mg daily) decreased the
elimination of several drugs, including carbamazepine (Wright et al. 1982), diazepam
(Ochs et al. 1981), triazolam (Ochs et al. 1983), vincristine (Chan et al. 1998),
theophylline (Samigun et al. 1990), disulfiram (Whittington et al. 1969),
chlorzoxazone and paracetamol (Zand et al. 1993). In addition, a commonly prescribed
daily dose of isoniazid (300 mg daily) markedly increased serum phenytoin
concentrations, with resultant toxicity in some patients (Kutt et al. 1968; Miller et al.
1979). A recent in vitro study has shown that isoniazid inhibited CYP2C19 and 3A4
activities in human liver microsomes, with Ki values of 25 µM and 52 µM,
respectively (Desta et al. 2001).
8.4. Trimethoprim
Pharmacokinetics Trimethoprim is frequently combined with sulfamethoxazole
(cotrimoxazole) to treat a wide range of infections. Trimethoprim is rapidly and
completely absorbed following oral administration, and its Cmax is 1 to 4 h, and
approximately 5.8 mg/l (about 20 µM) following oral administration of trimethoprim
200 mg twice daily (Moore et al. 1996). The t1/2 of trimethoprim is about 10 h.
Trimethoprim exhibits moderate plasma protein binding (42%-46%) (see Dollery
1999) (Table 3).
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Metabolism Trimethoprim is mainly excreted unchanged in urine, while a small
proportion (20%) of a dose is metabolised by the hepatic CYP forms (Gleckman et al.
1981) (Fig 6; Table 3). In some individuals with severe liver damage, the t1/2 of
trimethoprim can be lengthened by up to 2-fold (Rieder et al. 1975).
Drug-drug interactions In humans, trimethoprim and sulfamethoxazole used alone at
normal therapeutic doses have inhibited the metabolic clearance of tolbutamide (by
14% and 14%, respectively) and phenytoin (by 30% and 10%, respectively) (Wing &
Miners 1985; Hansen et al. 1979). The use of the combinanation of trimethoprim and
sulfamethoxazole (1:5), increased the AUC of S-warfarin by about 20% (O'Reilly
1980), and inhibited the metabolic clearance of tolbutamide by about 25% (Wing &
Miners 1985). In in vitro studies, sulfamethoxazole competitively inhibits tolbutamide
hydroxylase activity, with Ki values of 246 µM or 283 µM in human liver microsomes
(Back et al. 1988; Komatsu et al. 2000b).
8.5 Sulfamethoxazole
Pharmacokinetics Sulfamethoxazole is readily absorbed from the gastro-intestinal
tract and its Cmax is reached about 2 h postdose (Parfitt 1999). Its Cmax is approximately
26-63 mg/l (103-250 µM) after sulfamethoxazole oral 800 mg twice daily (Kaplan et
al. 1973; Dollery 1999). The t1/2 is about 9 h, and the plasma protein binding is about
66% (Dollery 1999) (Table 3).
Metabolism Sulfamethoxazole mainly undergoes acetylation (60%) in the liver, while
a minor part of sulfamethoxazole is subject to oxidative metabolised by CYP2C9 to
the hydroxylamine, a metabolite that has been implicated in adverse reactions to
sulphonamides (Cribb et al. 1995; Parfitt 1999) (Fig 6; Table 3).
Drug-drug interactions (see Drug-drug interactions in 8.4)
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AIMS OF THE STUDY
The specific aims of the study were:
1. Evaluation of the effects of valproic acid, gemfibrozil, isoniazid, trimethoprim and
sulfamethoxazole on CYP1A2-, CYP2A6-, CYP2C8- (only in Study IV),
CYP2C9-, CYP2C19-, CYP2D6-, CYP2E1- and CYP3A4-mediated reactions
(Study I-IV).
2. Prediction of the potential in vivo drug-drug interactions using the in vitro enzyme
kinetic data and a scaling model (Study I-II, IV) and evaluation of their clinical
relevance.
3. Examination of the effects of Hsa and Hlc on the in vitro enzyme kinetics of the
formation of hydroxytolbutamide (CYP2C9 marker reaction), and on the inhibitory
effect of gemfibrozil on tolbutamide hydroxylation using human liver microsomes
(Study V).
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1. In vitro enzyme-assay systems
1.1 Human liver microsomal studies
Pooled human liver microsomes (prepared from five male and five female human liver
microsomal samples) known to contain high levels of CYP1A2, 2A6, 2C8, 2C9, 2C19,
2D6, 2E1 and 3A4 were obtained from Gentest Corp. (Woburn, MA). The liver
samples were obtained from several organ procurement organizations, which collect
tissues in accordance with all the pertinent regulations and obtain permission from the
donors' families prior to organ collection. The procedures of these organizations have
all been reviewed and approved by their respective institutional Human Subjects
Committee. The same pooled batch was used in all of the in vitro studies (Study I-V).
The microsomes were frozen and kept at -80°C until used.
Eight (CYP1A2, 2A6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4) CYP form-specific marker
reactions were studied in the present studies (Table 4). Phenacetin O-deethylation was
used to probe for CYP1A2, coumarin 7-hydroxylation for CYP2A6, paclitaxel 6α-
hydroxylation for CYP2C8 (used in Study IV only), tolbutamide hydroxylation for
CYP2C9, S-mephenytoin 4′-hydroxylation for CYP2C19, dextromethorphan O-
demethylation for CYP2D6, chlorzoxazone 6-hydroxylation for CYP2E1, midazolam
1′-hydroxylation and testosterone 6β-hydroxylation (used in Study IV only) for
CYP3A4.
All incubations were performed using an incubation medium containing 0.1 M sodium
phosphate buffer (pH 7.4), 5 mM MgCl2, and 20 µg human liver microsomes (original
concentration 20 mg/ml) in a final incubation volume of 0.2 ml. The candidate
inhibitors were preincubated with the incubation medium at 37°C for 15 min, either in
the presence or absence of 1.0 mM NADPH. After the preincubation, the probe
substrates were added either with or without 1.0 mM NADPH for measurement of the
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corresponding marker activities. Concentrations of the probe substrates used were
chosen around appropriate apparent Km values. After a specific incubation time, the
reactions were terminated by adding the appropriate chemicals to precipitate the
proteins. The detailed assay conditions for each CYP marker reaction are described in
Table 4. All incubations were performed in duplicate and in the linear range with
respect to the microsomal protein concentration, the substrate concentration ranges
used and the incubation time.
In Study I, six form-selective CYP inhibitors were used as positive controls at
appropriate concentrations, i.e. furafylline (1 and 5 µM) for CYP1A2, sulfaphenazole
(3.6 and 100 µM) for CYP2C9, tranylcypromine (50 and 100 µM) for CYP2C19,
quinidine (1 and 5 µM) for CYP2D6, pyridine (20 and 80 µM) for CYP2E1 and
troleandomycin (20 and 100 µM) for CYP3A4. The final concentrations of each
inhibitor were chosen according to previous publications (Hargreaves et al. 1994;
Newton et al. 1995; Eagling et al. 1998; Hickman et al. 1998). As furafylline and
troleandomycin are mechanism-based inhibitors, they were preincubated for 15 min
with the incubation medium in the presence of NADPH before adding the
corresponding marker substrates (Fig 7).
1.2 Recombinant human CYP form studies
Microsomes from baculovirus-infected insect cells engineered to express the cDNA
encoding human CYP2C8 and CYP2C9 (Gentest Corp., Woburn, MA) were used in
Study IV. The supersomes of the expressed enzymes were frozen and kept at -80°C
until used.
Incubations with the recombinant CYP2C8 and CYP2C9 forms were performed using
the same conditions as the corresponding assays for CYP2C8 and CYP2C9 activities
in human liver microsomes, except that the incubation mixture contained 100 µg/ml of
CYP2C8 and CYP2C9 supersomes (original concentrations of 3 mg/ml for CYP2C8,
and 2.1 mg/ml for CYP2C9), and was incubated for 20 min (CYP2C8), and 30 min
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 (CYP2C9) with the probe substrates, respectively. All incubations were performed in
duplicate and in linear range with respect to the microsomal protein concentration, the
substrate concentration ranges used and the incubation time.
2. Design of the inhibition studies
In order to estimate the inhibitory potencies of the candidate compounds (Study I-IV)
against the major human CYP form activities, a fixed concentration of the marker
substrates (around their corresponding Km values) was coincubated with various
concentrations of a candidate inhibitor. The IC50 and Ki values were characterized
when the tested drugs produced dose dependent inhibitory effects on the probe
reactions. To determine the values of IC50 and Ki, the concentration of the marker
substrates were chosen around their corresponding Km values, and about 0.5- 4 fold of
their corresponding Km values, respectively. Additionally, to test whether the
inhibition of CYP forms by the candidate compounds could be mechanism-based, the
compounds were preincubated with the incubation medium at 37°C for 15 min, either
in the presence or absence of 1.0 mM NADPH. In the case of NADPH-dependent
inhibition (in Study I and III), the inhibitor was preincubated with the incubation
medium for 0, 2, 5, 10 and 15 min in the presence or absence of 1.0 mM NADPH
before adding corresponding marker substrates.
The range of concentrations used for each compound tested were as follows: valproic
acid, 50 to 25000 µM (dissolved in 0.1 M sodium phosphate buffer, pH 7.4);
gemfibrozil, 2.5 to 250 µM [dissolved in acetonitrile, then acetonitrile was evaporated
to dryness and the residue was reconstituted using the incubation medium (it has been
validated by HPLC assay that gemfibrozil with concentrations up to 250 µM was
totally dissolved in the incubation medium)]; isoniazid, 2.5 to 250 µM [prepared in
water with a minimal (0.2%) use of methanol]; trimethoprim, 5 to 500 µM, and
sulfamethoxazole, 50 to 1000 µM (stock solutions of trimethoprim and
sulfamethoxazole were dissolved in methanol, and 2 µl of each stock solution was
added to the incubation medium with a final volume of 200 µl, i.e. the final
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concentration of methanol was 1%). The same concentrations of the solvents used
were added to the corresponding control samples, to minimize the effects of the
organic solvents.
3. Effects of Hsa and Hlc on the enzyme kinetics of tolbutamide hydroxylation
and on the inhibition of CYP2C9 by gemfibrozil
Pooled Hlc (prepared from 5 male and 5 female human liver samples) obtained from
Tebu International Co. (Paris, France), and Hsa (analytical grade, fatty acid free)
purchased from Sigma Chemical Co. (St. Louis, MO) were used in Study V.
Unbound fractions of tolbutamide and gemfibrozil in incubation media containing
microsomal protein (0.1 mg/ml), Hsa (0.5-5 mg/ml) and Hlc (0.5-5 mg/ml) were
separated by ultrafiltration (Sallustio et al. 1997; Carlile et al. 1999). In brief,
tolbutamide (5-1000 µM) and gemfibrozil (10-100 µM) were prepared in each of the
media used in the microsomal incubations, but without NADPH. After preincubation
at 37 °C for 30 min in the absence of Hsa and Hlc, and in the presence of Hlc, and for
120 min in the presence of Hsa, and Hsa plus Hlc (the preincubation times used were
validated by pilot tests to attain equilibrium binding), the samples were centrifuged for
30 min at 37 °C in a micropartition filter (Centrifree, part no 4104; Amicon Co, MA).
After the centrifugation, an aliquot of the ultrafiltrate was subjected to analysis of the
unbound drug concentration by HPLC.
The various concentration ranges of the marker substrates used for the kinetic analysis
(Study I, IV-V) as well as their assay conditions have been specified in Table 4.
In Study V, tolbutamide (5-1000 µM) was preincubated with the incubation medium at
37°C for 30 min in the absence of Hsa and Hlc, and in the presence of Hlc (0.5-5
mg/ml), and for 120 min in the presence of Hsa (0.5-5 mg/ml), and Hlc plus Hsa. The
reaction was initiated by the addition of 1.0 mM NADPH followed by 0.1 mg/ml
microsomes. The time of incubation and concentration of microsomal protein used in
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the assay were determined to be in the linear range for the rate of hydroxytolbutamide
formation. After incubation for 60 min, the reactions were terminated by adding 20 µl
phosphoric acid (85%) to precipitate the proteins.
4. HPLC analysis
Assays for the products of the CYP marker reactions were carried out using HPLC, as
described previously (Chauret et al. 1997; Ko et al. 1997; Wester et al. 2000; Raucy et
al. 1997; Ha et al. 1993; Stewart et al. 1986; Harris et al, 1994; Wang et al. 2000b).
The HPLC system consisted of a Pharmacia LKB 2150 pump (LKB, Uppsala,
Sweden), a Hewlett-Packard 1050 autosampler (Hewlett Packard), a Hewlett-Packard
3396 integrator (Hewlett Packard), a SPD-10AV Shimadzu UV-detector (Shimadzu,
Kyoto, Japan) (for analysis of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and
CYP3A4 activities), a RF-551 Shimadzu fluorescence detector (Shimadzu; for analysis
of CYP2A6 and CYP2D6 activities) or Model 5100A Coulochem electrochemical
detector (ESA Inc., Bedford, MA; for analysis of the inhibitory effect of
sulfamethoxazole on CYP2E1 activity). The intraday and interday coefficients of
variation for all assays were less than 7% at the relevant concentrations (n = 6). The
analytical methods for the in vitro assays are summarized and listed in Table 5.
5. Data Analysis
The IC50 values were determined graphically. The total apparent Km and Vmax (or the
unbound apparent kinetics, i.e. Km, u and Vmax, u, determined only in Study V for the
formation of hydroxytolbutamide) for the CYP form-selective marker reactions, and
the total Ki (or the unbound Ki determined in Study V for the inhibition of formation of
hydroxytolbutamide by gemfibrozil) values of the tested drugs were calculated by
nonlinear regression analysis. Different models of enzyme kinetics [equations (1) and
(2), see Review of the Literature, section 2] or enzyme inhibition [equations (3), (4),
(5) and (6), see Review of the Literature, section 3.1.1], i.e. competitive,
noncompetitive, uncompetitive and mixed-type inhibition, were fitted to the data
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(Segel 1975). An assessment of goodness of fit of the models was made using the size
of the residual sum of squares, the random distribution of the residuals, the standard
error, and the 95% confidence interval of the parameter estimates (Motulsky &
Ransnas 1987).
In the case of preincubation time dependent CYP inactivation (Study I and III), T1/2
was estimated from linear regression analysis of the natural logarithm of residual
enzyme activity against preincubation time. The concentrations required for KI and
Kinact were estimated by fitting data to the equation (11) (see Review of the Literature,
section 6.1).
The in vivo (i) values of valproic acid, gemfibrozil, trimethoprim and
sulfamethoxazole, which showed no preincubation time dependent inhibition, were
predicted by the scaling model [ equation (13), see Review of the Literature, section
6.2], where (I) represents the inhibitor concentration around the metabolic enzyme site.
Because the real in vivo (I) is unknown, the free or total drug concentration in plasma
(Study I, II, and IV) or the total plasma drug concentration multiplied by the
liver/plasma partition ratio taken from animal experiments (Study IV) was used in the
calculation.
In study V, a single enzyme MM model [equation (1), see Review of the Literature,
section 2] was found to be the best fit enzyme model relating hydroxytolbutamide
formation rates to the concentrations of either total or unbound tolbutamide (S).
Additionally, competitive inhibition [equation (3), see Review of the Literature,
section 3.1.1] was found to be the best fit enzyme model for the inhibition of CYP2C9
by gemfibrozil either in the presence or absence of Hsa and/or Hlc. The in vitro total
(or unbound) intrinsic clearance Clint (or Clint, u) values was calculated using Vmax/Km
(or Vmax, u/Km, u). The in vitro Clint (or Clint, u) values were scaled to in vivo using the
standard scaling factors of 45 mg microsomal protein/g liver and 20 g liver/kg body
weight for humans (Obach 2000). The Clh values were calculated using the well-
stirred model:
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Clh = Q ⋅ fu ⋅ Clint / (Q + fu ⋅ Clint)
where Q is 20 ml/min/kg (Lin & Lu 1997), and fu is the unbound fraction of
tolbutamide in the blood (0.03; Dollery 1999).
6. Statistical analyses
In Study V, the t-test was used to compare the observed in vivo metabolic clearance of
tolbutamide with that predicted from literature microsomal data. The unbound
fractions of tolbutamide and gemfibrozil in incubation media in the presence or
absence of 5 mg/ml Hsa, and 0.5 mg/ml Hlc were compared using the Wilcoxon test
(in Study V).
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RESULTS
1. Enzyme kinetics and known inhibitors of human liver CYP enzymes
The apparent Km and Vmax values for each CYP marker reaction (Table 4) were in
agreement with previous literature results. The effects of form-selective inhibitors on
these CYP activities were similar to those reported previously (Fig 7).
2. Inhibition studies
2.1 Valproic acid
In vitro, valproic acid preferentially and competitively inhibited CYP2C9-catalysed
tolbutamide hydroxylation with an apparent Ki value of 600 µM, while it was a mixed-
type inhibitor for CYP2C19 (Ki = 8553 µM) and a competitive type inhibitor for
CYP3A4 (Ki = 7975 µM) activities (Table 6). In addition, inhibition of CYP2A6-
catalysed coumarin 7-hydroxylation by valproic acid was found to be preincubation
time- and concentration-dependent with a Kinact of 0.048 min-1 and KI of 9150 µM
(Table 6). However, only minimal inhibition of CYP1A2, CYP2D6 and CYP2E1
activities by valproic acid was observed.
2.2 Gemfibrozil
Gemfibrozil competitively inhibited CYP2C9-catalysed tolbutamide hydroxylation
with a Ki (IC50) value of 5.8 (9.6) µM (Table 6). In addition, gemfibrozil exhibited a
modest but significant inhibitory effect on CYP2C19 and CYP1A2 activities with an
apparent Ki (IC50) values of 24 (47) µM and 82 (136) µM, respectively (Table 6). The
pattern of inhibition of CYP2C19 and CYP1A2 by gemfibrozil was compatible with
mixed-type inhibition. With concentrations ranging from 5 to 250 µM, gemfibrozil
showed no remarkable effects on CYP2A6, CYP2D6, CYP2E1, and CYP3A4
activities.
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2.3 Isoniazid
Isoniazid preferentially inhibited CYP2C19- and CYP3A4-mediated reactions after a
15 min preincubation without NADPH. The double-reciprocal plots and Dixon plots
consistently indicated that isoniazid competitively inhibited CYP2C19 activity with a
Ki of 36 µM, and uncompetitively inhibited CYP3A4 with a Ki value of 73 µM (Table
6). However, isoniazid had only very weak inhibitory effects on CYP1A2, CYP2A6,
CYP2C9, CYP2D6 and CYP2E1 activities (Ki > 110 µM). After a 15 min
preincubation with NADPH, isoniazid showed an increased inhibitory potency toward
CYP1A2, CYP2A6, CYP2C19 and CYP3A4 activities. The estimated Ki values of
isoniazid for CYP1A2, CYP2A6, CYP2C19 and CYP3A4 activities (Ki = 56, 60, 10
and 36 µM, respectively) were markedly lower in the presence of NADPH than in the
absence of NADPH during preincubation (Table 6). In addition, the inactivation of
these CYP forms by isoniazid was found to be preincubation time-, and concentration-
dependent, and was characterized by Kinact values of 0.11, 0.13, 0.09 and 0.08 min-1,
and KI values of 285, 173, 112 and 228 µM, respectively (Table 6).
2.4 Trimethoprim
With concentrations ranging from 5 to 100 µM, trimethoprim exhibited a selective and
competitive inhibitory effect on CYP2C8-mediated paclitaxel 6α-hydroxylation with
an apparent IC50 (Ki) value of 54 µM (32 µM) in human liver microsomes, and an IC50
of 75 µM in recombinant CYP2C8 (Table 6). However, trimethoprim lost its form-
selectivity at concentrations higher than 100 µM. As much as 20%-50% of CYP1A2-,
CYP2C9-, CYP2C19-, CYP2D6- and CYP3A4 activities were inhibited at 250 µM or
500 µM of trimethoprim.
2.5 Sulfamethoxazole
With concentrations ranging from 50 to 500 µM, sulfamethoxazole selectively and
competitively inhibited tolbutamide hydroxylase activity in human liver microsomes
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and recombinant CYP2C9, with apparent IC50 (Ki) values of 544 µM (271 µM) and
456 µM, respectively (Table 6). Very little (< 20%) or no inhibition of other CYP
forms was found in this concentration range. However, at concentrations higher than
500 µM, sulfamethoxazole showed a modest (30-40%) inhibitory effect on CYP2A6-
mediated coumarin 7-hydroxylation, and CYP3A4-mediated midazolam 1′-
hydroxylation. Interestingly, sulfamethoxazole only very slightly inhibited CYP3A4-
mediated testosterone 6β-hydroxylation which was as high as 1000 µM.
3. Prediction of drug-drug interactions of valproic acid, gemfibrozil,
trimethoprim and sulfamethoxazole in vivo
Based on the scaling model, assuming that the concentration of valproic acid at the
enzyme site equals its mean peak total plasma concentration (about 450 µM), valproic
acid would cause approximately 40% inhibition of the hepatic clearance of CYP2C9
substrates (Table 7). However, using the mean unbound plasma concentration (about
45 µM) of valproic acid in the calculation, valproic acid would cause approximately
7% inhibition of the metabolic clearance of CYP2C9 substrates (Table 7).
The predicted in vivo inhibitory effects of gemfibrozil, trimethoprim, and
sulfamethoxazole on CYP form activities are summarized in Table 7.
4. Effects of Hsa and Hlc on the enzyme kinetics of tolbutamide hydroxylation
and on inhibition of CYP2C9 by gemfibrozil
4.1 Survey of the in vitro and in vivo literature data regarding the metabolism of
tolbutamide
Six separate in vitro studies on the formation of hydroxytolbutamide (Doecke et al.
1991; Hemeryck et al. 1999; Shin et al. 1999; Komatsu et al. 2000a; Hickman et al.
1998; Miners et al. 1988) including 20 individual human liver microsomal samples
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were summarized. The inclusion of these studies was based on the critical criteria (see
the original manuscript, Study V, for details). The predicted in vivo Clh values of
tolbutamide based on these data were considerablely lower than the values of actual
metabolic clearance of hydroxytolbutamide (Clmet) (0.059 ml/min/kg vs 0.15
ml/min/kg), adopted from a clinical pharmacokinetic study on 10 healthy subjects
[Gross et al. 1999, the Clmet values were calculated by dividing the sum amount of
hydroxytolbutamide and carboxytolbutamide excreted during a 32 hours interval by
the total area under the tolbutamide plasma concentration time curve from 0 to 32-
hour (AUC0-32), and were normalized by body weight in kg].
Table 7 Summary of the predicted in vivo inhibition (%) of the metabolism of
coadministered CYP substrates by valproic acid, gemfibrozil, trimethoprim, and
sulfamethoxazole, respectively, from in vitro data using the scaling model: I/(I + Ki) α
CYP forms Valproic acid Gemfibrozil Trimethoprim Sulfamethoxazole
CYP1A2 - 64 (8) - -
CYP2C8 - - 80 [26] -
CYP2C9 40 (7) 96 (56) - 13 [24]
CYP2C19 - 86 (24) - -
α
 : The model supposes that the substrate concentration for CYP is much lower than its Km
value.  In the cases of prediction with valproic acid and gemfibrozil, the I values used in
the model were the total (or unbound) Cmax of valproic acid [450 (45) µM, Davis et al.
1994; Dollery 1999] and gemfibrozil [150 (2) µM, Backman et al. 2000; Dollery 1999]. In
the cases of prediction with trimethoprim and sulfamethoxazole, the I values were the total
hepatic concentrations of trimethoprim (130 µM) and sulfamethoxazole (40 µM),
estimated using the total plasma concentration of trimethoprim (20 µM) and
sulfamethoxazole (250 µM) multiplied by the liver/plasma partition ratios of monkeys (6.5
and 0.15 for trimethoprim and sulfamethoxazole, respectively) or [free plasma
concentrations of trimethoprim (11 µM) and sulfamethoxazole (85 µM)] (see the original
publications for details).
- : not calculated, negligible inhibition.
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4.2 Effects of Hsa and Hlc on the unbound concentrations of tolbutamide and
gemfibrozil
Tolbutamide or gemfibrozil at 50 µM did not bind with the incubation buffer including
0.1 mg/ml microsomal proteins. Concentrations of 0.5-5 mg/ml Hsa and Hlc dose-
dependently decreased the unbound fractions of tolbutamide and gemfibrozil, but the
effects of Hlc were much smaller than those of Hsa. The lowest, 0.5 mg/ml
concentration of Hlc had no statistically significant effect on the unbound fractions of
tolbutamide (5-250 µM) and gemfibrozil (10-100 µM) (P> 0.05). However, at a fixed
5 mg/ml concentration of Hsa, the unbound fractions of tolbutamide (5-250 µM) and
gemfibrozil (10-100 µM) increased with increasing drug concentrations. The co-
addition of Hsa and Hlc yielded no apparent difference (P> 0.05) in the unbound
fractions of tolbutamide and gemfibrozil compared to Hsa alone.
4.3 Effects of Hsa and Hlc on the enzyme kinetics of tolbutamide hydroxylation
The MM and Eadie-Hofstee plots consistently indicated that a single enzyme played a
predominant role in the formation of hydroxytolbutamide in all the incubation
mixtures. The apparent Km, and Vmax values in the standard incubation media were 123
µM, and 282 pmol/mg/min, respectively. Based on these estimates, the predicted Clh, u
value for tolbutamide  (0.06 ml/min/kg) was 2.5 fold lower than the actual in vivo data
(0.15 ml/min/kg). The addition of 5 mg/ml Hsa or 0.5 mg/ml Hlc to the microsomal
incubation media greatly decreased the unbound Km of the formation of
hydroxytolbutamide (73 µM or 88 µM, respectively), making the predicted Clh, u
values much closer to the in vivo data (0.11 or 0.09 ml/min/kg, respectively). The co-
addition of Hsa and Hlc yielded the predicted Clh, u value (0.14 ml/min/kg) which was
closest to the in vivo data (0.15 ml/min/kg).
4.4 Effects of Hsa and Hlc on inhibition of CYP2C9 by gemfibrozil
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Gemfibrozil dose-dependently inhibited tolbutamide hydroxylase, with an IC50 value
of 13 µM in the absence of Hsa and Hlc in the incubation media. Considering the total
gemfibrozil concentrations, the inhibitory effects of gemfibrozil on tolbutamide
hydroxylase were greatly decreased by the addition of 5 mg/ml Hsa, 0.5 mg/ml Hlc, or
both to the incubation media, with the IC50 values of 67 µM, 24 µM or > 100 µM,
respectively. Consistently, the Ki (6 µM) of gemfibrozil for CYP2C9 calculated using
the total drug concentrations was increased by Hlc (8 µM), Hsa (40 µM) or both (72
µM). However, considering the unbound tolbutamide and gemfibrozil concentrations
in the calculation, the Ki (6 µM, in the absence of Hsa and Hlc in the incubation
media) was not significantly altered by the addition of Hsa (4 µM), Hlc (8 µM) or both
Hsa and Hlc (9 µM) (Table 8).
Table 8 The inhibitory effects of gemfibrozil for CYP2C9-mediated tolbutamide
hydroxylation in human liver microsomes in the absence and presence of 5 mg/ml Hsa and
0.5 mg/ml Hlc
Ki (µM)Incubation
Total a Unbound b
Without Hsa and Hlc 6 6
With Hlc 8 8
With Hsa 20 (40)c 4
With Hsa and Hlc 36 (72)c 9
The Ki values were estimated using nonlinear regression analysis.
a
 Total Ki of gemfibrozil estimated using the competitive inhibition model: Vi = Vmax ⋅ Su /
[Km (1 + I / Ki) + Su], where S u is the unbound tolbutamide concentration, and I is the total
gemfibrozil concentration.
b
 Unbound Ki of gemfibrozil estimated using Vi = Vmax ⋅ Su / [Km (1 + Iu / Ki) + Su], where S u
is unbound tolbutamide, and Iu is unbound gemfibrozil.
c
 Total Ki of gemfibrozil estimated using Vi = Vmax ⋅ S / [Km (1 + I / Ki) + S], where S is total
tolbutamide, and I is total gemfibrozil.
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DISCUSSION
1. Methodological considerations
1.1 In vitro enzyme-assay system
In the present studies, pooled human liver microsomes were used for evaluating the
effects of the selected drugs on the major CYP activities. Although the human liver
microsomal system is probably the most feasible system for the study of drug
metabolism and drug-drug interactions in vitro (Levy et al. 2000), this system has its
limitations (see Review of the Literature, section 4). To circumvent the interindividual
variability in CYP activities, a large pooled human liver microsome batch (5 male and
5 female individual donors) was used in the present studies to provide average data
about the evaluated compounds as inhibitors of CYP forms. A range of values rather
than an average value is often preferred in in vitro-in vivo extrapolation studies,
especially when studying the contributions of different forms to a metabolic reaction
(Tucker et al. 2001). However, due to the inability to match healthy volunteer subjects
with human tissue donors, interindividual variability cannot be totally avoided even
using individual microsomal samples (Carlile et al. 1999). Therefore, the use of pooled
liver microsomes more precisely represents the population average than the use of a
limited amount of individual microsomal samples, and is more appropriate for scaling
in vitro clearance data to in vivo data (Obach 1997). In addition, the pooled
microsomal batch used had been confirmed to contain representative activities of
individual CYP forms. For example, the characterized Km and Vmax values for the
individual CYP forms from the pooled microsomes conformed well to those
previously reported in the literature (Study I, IV and V). In any case, it should be noted
that any conclusions about interindividual variability of the inhibitory potency of the
drugs studied could not be drawn from the present studies due to the use of pooled
microsomes.
Recombinant CYP forms were used in Study IV. Because recombinant enzymes used
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expressed only a single CYP form activity, they can be used for further evidence that
the inhibition of a certain reaction is due to inhibition of a specific CYP form.
However, it should be noted that recombinant CYP forms expressed in different
chimeras might have different enzyme activities, and that the enzyme activities
expressed may substantially differ from those of the native human enzymes (Yamazaki
et al. 1997). In addition, this system has serious limitations in inhibition studies, and is
not suitable for the study of mechanism-based inhibition when the target enzyme
studied is not responsible for the metabolism of the mechanism-based inhibitor
(Moody et al. 1999). Therefore, it can only be used as a complementary and screening
tool for human liver microsomes.
The choice of incubation conditions such as ionic strength, and the pH value of the
incubation medium may influence the outcome of in vitro studies (Venkatakrishnan et
al. 2001). We routinely use 0.1 M sodium phosphate buffer (pH 7.4) as the incubation
medium, which in principle parallels the ionic strength and pH of hepatic cytoplasma
in vivo. In addition, the effects of organic solvents on CYP activities are also of great
concern. As most drugs have poor aqueous solubility in incubation media, organic
solvents are commonly used to dissolve them. However, organic solvents can potently
and selectively inhibit CYP enzymes (Hickman et al. 1998; Chauret et al 1998; Busby
et al. 1999). For example, the 1% (v/v) methanol used in an incubation did not inhibit
CYP2C19 and 3A4 activities, but markedly inhibited CYP2E1 and CYP2C9 activities
by about 30% (Chauret et al. 1998). The other commonly used organic solvents, i.e.
accetonitrile, ethanol and dimethyl sulfoxide (DMSO), have also somewhat significant
inhibitory affects on certain CYP activities (Hickman et al. 1998; Chauret et al 1998;
Busby et al. 1999). Accordingly, the final concentration of the organic solvent used in
the in vitro incubations should be minimised as much as possible. In the present
studies, the stock solutions of the tested compounds were dissolved in methanol,
acetonitrile or ethanol, and subsequently diluted using the reaction buffer. The final
concentrations of the organic solvents in the incubations were kept as low as possible
and constant in the incubation series. The final solvent concentration in incubation did
not exceed 1% (v/v). Furthermore, the control samples were made with an equal
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concentration of the respective solvent. The final organic solvent concentrations used
in the incubations are summarised and listed in Table 4.
Besides the factors mentioned above, the amount of microsomal protein and
incubation time used are also very important for the in vitro studies. Drugs can bind to
the microsomal protein in a manner that influences their ability to inhibit the enzyme
being evaluated (Rodrigues 2002). Furthermore, a long incubation time and a large
amount of protein may cause the drug to be significantly metabolised during the
incubation. The consequence of both excessive binding and excessive metabolism is
that the concentration of the drug available for metabolism or inhibition of the CYP
mediated reaction may be significantly reduced during the incubation (Gibbs et al.
1999; Obach 1996; 1997; 1999). Accordingly, in our studies, a low microsomal
protein concentration (100 µg/ml) was used in all of the incubations. In addition, the
time of incubation (Table 4) and the concentration of microsomes or supersomes used
(100 µg/ml) were determined to be in the linear range for the rate of metabolite
formation for each substrate.
In the present series of studies, to determine whether the inhibition of CYP forms by
drugs could be mechanism-based, the studied drugs were preincubated with the
incubation medium at 37°C for 15 min, either in the presence or absence of NADPH.
An excessive inhibitory effect (more than 30%), after preincubation of drugs with
NADPH, may suggest a potential mechanism-based inhibition (Rodrigues 2002).
These kinds of studies are important to avoid underestimation of the in vitro inhibitory
potencies of the studied drugs.
Finally, six form-selective CYP inhibitors were used as positive controls at appropriate
concentrations to validate the present in vitro enzyme-assay systems (Fig 7). The
results clearly indicated that each positive control inhibitor inhibited their targeted
enzyme activity in agreement with previous reports (Hargreaves et al. 1994; Newton et
al. 1995; Eagling et al. 1998; Hickman et al. 1998). Tranylcypromine was used as an
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inhibitor of CYP2C19. However, it also potently inhibits CYP2A6 (Taavitsainen et al.
2001; Zhang et al. 2001).
1.2 Experimental designs
Eight different CYP form-specific marker reactions were studied in the present studies.
In the case of CYP3A4, the potency of inhibition of a drug has been shown to be
dependent on the choice of the marker substrate, because the active site of CYP3A4 is
sufficiently large and flexible to allow simultaneous binding of two or more molecules
of which one can be an activator or inhibitor (Schrag & Wiekers 1999; Rodrigues
2002). In order to achieve a better evaluation of the effects of a drug on CYP3A4
activity and to be able to extrapolate the in vitro findings to the clinical situation, it is
probably safer to study CYP3A4 inhibition using several marker substrates. Therefore,
both midazolam 1′-hydroxylation and testosterone 6β-hydroxylation were used as
CYP3A4 marker reactions in Study IV.
The selection of appropriate concentrations of the marker substrates is another
important issue in design of in vitro studies. The selection of the concentrations of a
marker substrate can largely affect the kinetic parameters of the enzyme reaction (Km,
Vmax and Ki values) and the type of inhibition. The ''appropriate range'' of the substrate
concentrations is between 0.5 Km and 4 Km (Rodrigues 2002). Consistent with this, the
substrate concentrations used in the present studies were in the range of 0.5 ∼ 4 Km
(Table 4). In addition, the selection of the concentrations of a chemical inhibitor
should be carefully considered. Normally, the concentrations of the drug were selected
on the basis of the known in vivo Cmax of the drug. However, considering that many
lipophilic drugs are concentrated in the liver, the concentration of a lipophilic inhibitor
at the active site of the CYP enzymes may be higher than its plasma Cmax (von Moltke
et al. 1998). Also, a significant portion of lipophilic drugs may bind to microsomal
proteins and lipids in the incubation media, thus reducing the ''free'' drug available to
inhibit the enzyme (Obach 1996; 1997; 1999). Therefore, in the present studies, the
lipophilic drugs evaluated, i.e. valproic acid, gemfibrozil, trimethoprim and
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sulfamethoxazole (Parfitt 1999), were used at very high concentrations (i.e.
approximately 10-fold their Cmax) in the inhibition studies, to exclude the possibility of
false negative results.
A relatively low Hsa concentration (5 mg/ml, 0.5%) was used in Study V. The
concentration of albumin in cultured rat hepatocyte S-9 fractions (contains the
cytosolic and microsomal factions) has been about 65 mg/g proteins, i.e. 6.5% of total
protein weight (Milosevic et al. 1999). Although the real in vivo concentration of
albumin around the metabolic enzyme site is not known, it is probably clearly lower
than the concentration of albumin in serum (about 4%). Thus, the addition of 0.5%
Hsa to in vitro microsomal incubations may more accurately reflect the physiological
conditions in vivo. Consistent with this postulation, a higher albumin concentration
(2%) used in the incubations, resulted in an overestimation of the in vivo metabolic
clearance of tolbutamide (Carlile et al. 1999).
1.3 In vitro-in vivo extrapolations
A scaling model, i.e. i = I/(I + Ki) was used to extrapolate the in vitro results to in vivo
ones. The use of this model is based on an assumption that the concentration of
substrate is substantially less than Km i.e. S << Km in the case of competitive inhibition
(see Review of the Literature, section 6.3). However, in some cases, this approach
overestimates the inhibitory potency, because S is actually near the K m, or even higher
than the Km. In some cases, the ''free'' plasma concentration of an inhibitor was used as
(I) in the scaling model, owing to an assumption that only the free drug can perfuse
into the liver. However, for lipophilic compounds, their liver concentrations may far
exceed their ''free'' plasma concentrations (von Moltke et al. 1998). For example,
valproic acid would cause approximately 40% (or 7%) inhibition of the hepatic
clearance of CYP2C9 substrates using the mean (450 µM) (or unbound, 45 µM)
plasma concentration to predict in vivo situation. However, in vivo, valproic acid at a
serum concentration of about 400 µM, reduced the systemic clearance of unbound
phenytoin by 23% (Perucca et al. 1980). The decrease is about half or three times
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larger than what would be expected on the basis of total or unbound valproic acid
plasma concentrations. Simply put the total or unbound plasma concentrations of an
inhibitor may not directly relate to its hepatic concentration around the metabolic
enzyme sites. Predictions based on the predictive model is not straightforward.
In Study IV, the liver/plasma partition ratios of drugs in monkeys were used to
estimate the total hepatic trimethoprim and sulfamethoxazole concentrations.
However, due to the different species used, the estimated results may still be different
from the real values. Therefore, it should be kept in mind that although the predicted
results based on the above model can provide valuable information, they are only
rough estimations of the in vivo situations. The confirmation of such inhibition needs
more in vivo evidence.
2. Valproic acid, gemfibrozil, isonizaid, trimethoprim and sulfamethoxazole as
inhibitors of CYP forms
In our in vitro study, valproic acid preferentially inhibited CYP2C9 activity with the
Ki value of 600 µM, while it exhibited weak or no inhibitory effects on other CYP
forms. Although the plasma unbound valproic acid concentration is lower than 130
µM after a normal therapeutic dose (1000 mg daily), the concentrations of valproic
acid at the enzyme site in the liver could be disproportionately higher when its plasma
level approach or exceed the upper limit of the therapeutic range of valproic acid
(about 700 µM) to achieve seizure control (Davis et al. 1994). Thus, a significant
interaction between valproic acid and CYP2C9 substrates may occur in vivo. Inhibition
of CYP2C9 activity by valproic acid may explain the interactions between valproic
acid and phenytoin, diazepam, phenobarbitone and amitriptyline (Perucca et al. 1980;
Patel et al. 1980; Dhillon et al. 1982; Wong et al. 1996). Although valproic acid is an
inhibitor of CYP3A4 (Ki = 7975 µM) in vitro, the concentration of valproic acid may
be very high in the enterocytes during absorption. Consequently, inhibition of
intestinal CYP3A4 activity cannot be completely excluded. The observation that
inactivation of CYP2A6 activity by valproic acid involves time-, concentration-, and
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NADPH- dependence suggests that it is a mechanism-based inactivator of this CYP
form, a conclusion supported further by the finding that formation of 4-ene-valproic
acid, a minor metabolite of valproic acid, was mediated by CYP2A6 and CYP2C9 in
vitro (Sadeque et al. 1997).  However, as the inhibitory effect was weak, it is unlikely
that valproic acid significantly inactivates CYP2A6 at clinically relevant
concentrations. With the absence of an inhibitory effect on CYP1A2, CYP2D6 and
CYP2E1 activities, and the weak inhibition of CYP2C19 activity, valproic acid is
unlikely to produce clinically relevant interactions by inhibiting these CYP forms. This
conclusion is also in agreement with studies showing that valproic acid had no effect
on the plasma concentrations of the CYP1A2 substrates caffeine (Wietholtz et al.
1989) and clozapine (Facciola et al. 1999), and the CYP2D6 and CYP3A4 substrate
haloperidol (Hesslinger et al. 1999).
Gemfibrozil inhibited CYP2C9 activity with a Ki value of 5.8 µM, while it inhibited
CYP2C19 (Ki = 24 µM) and CYP1A2 (Ki = 82 µM) activities to a reduced extent in
human liver microsomes. The Ki values for CYP2C9, 2C19 and 1A2 fall in the range
of the total plasma concentrations of gemfibrozil (approximately 120-240 µM)
observed in humans after 600 mg gemfibrozil b.i.d. (Backman et al. 2000). Based on
the in vitro-in vivo scaling model: i = I/(I + Ki), using peak total (or unbound) plasma
concentration of gemfibrozil, 96% (56%), 86% (24%) and 64% (8%) inhibition of the
clearance of CYP2C9, 2C19 and 1A2 substrates by gemfibrozil could be expected,
respectively. Thus, inhibition of CYP2C9 activity by gemfibrozil is the likely
mechanism of the gemfibrozil-warfarin and gemfibrozil-glyburide interactions
(Rindone & Keng 1998; Ahmad 1990; 1991). In vivo, gemfibrozil increased the AUC
of glimepiride (a CYP2C9 substrate) by 23% (Niemi et al. 2001). It seems that the
predicted inhibition (24%) based on the unbound mean plasma concentration of
gemfibrozil (1.9 µM) is the most relevant data to the in vivo situation. On the other
hand, as gemfibrozil is not a CYP3A4 inhibitor in vitro, the gemfibrozil-simvastatin
and gemfibrozil-lovastatin interactions cannot be explained by inhibition of the
CYP3A4-mediated simvastatin and lovastatin metabolism, as is the case with
itraconazole-lovastatin and itraconazole-simvastatin interactions (Backman et al. 2000;
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Kyrklund et al. 2001). However, inhibition of some other pathways such as
glucuronidation (Prueksaritanont et al. 2002) that regulate the levels of the statin acids
by gemfibrozil cannot be ruled out.
In study III, isoniazid was found to be a mechanism-based inhibitor of CYP1A2, 2A6,
2C19 and 3A4 forms in human liver microsomes, with Kinact values of 0.11, 0.13, 0.09
and 0.08 min-1, and KI values of 285, 173, 112 and 228 µM, respectively. Because of
the difficulty to predict the in vivo inhibition of a mechanism-based inactivator, these
parameters were compared with those of other mechanism-based inactivators of CYPs
such as erythromycin (inactivated CYP3A4 activity, KI = 19 µM and Kinact = 0.064
min-1) (Ohyama et al. 2000), furafylline (inactivated CYP1A2 activity, KI = 23 µM
and Kinact = 0.87 min-1) (Kunze & Trager 1993), and delavirdine (inactivated CYP3A4
activity, KI = 22 µM and Kinact = 0.59 min-1) (Voorman et al. 1998). Considering that
the peak plasma concentrations of isoniazid (up to 50 µM) are higher than those of
erythromycin (5 µM) (Dollery 1999), furafylline (8 µM) (Dollery 1999) and
delavirdine (10 µM) (Tarrus et al. 1987), isoniazid may also be a mechanism-based
inactivator of human CYP2C19, 3A4, 1A2 and 2A6 in vivo although the KI values of
isoniazid are higher than those of above mentioned mechanism-based inactivators.
Consequently, inactivation of CYP1A2, CYP2A6, CYP2C19 and CYP3A4 activities
by isoniazid may explain the documented drug-drug interactions between isoniazid
and phenytoin (metabolised by CYP2C9 and 2C19), theophylline (metabolised by
CYP1A2 and 3A4), diazepam (metabolised by CYP2C19 and 3A4), triazolam
(metabolised by CYP3A4), paracetamol (metabolised by CYP2E1, 1A2, 3A4 and
2A6), chlorzoxazone (metabolised by CYP2E1 and 1A2), carbamazepine (metabolised
by CYP3A4), vincristine (metabolised by CYP3A4) and disulfiram (metabolised by
CYP2A6 and 3A4) (Kutt et al. 1968; Samigun et al. 1990; Ochs et al. 1981; 1983;
Zand et al. 1993; O'Shea et al. 1997; Wright et al. 1982; Chan 1998; Whittington et al.
1969).
In vitro, trimethoprim (5-100 µM) and sulfamethoxazole (50-500 µM) selectively
inhibited CYP2C8 (Ki = 32 µM) and 2C9 (Ki = 271 µM) activities, respectively. Thus,
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trimethoprim and sulfamethoxazole can be used as selective inhibitors for CYP2C8
and CYP2C9, respectively, in in vitro studies. With trimethoprim concentrations
higher than 100 µM and sulfamethoxazole concentrations higher than 500 µM, both
drugs lost their selectivity for the CYP forms. Based on the estimated total hepatic
concentrations (or free plasma concentrations) of the drugs and the scaling model, one
would expect in vivo in humans 80% (26%) and 13% (24%) inhibition of the
metabolic clearance of CYP2C8 and 2C9 substrates by trimethoprim and
sulfamethoxazole, respectively. Consistent with this prediction, trimethoprim and
sulfamethoxazole used alone inhibited the metabolic clearance of tolbutamide (14%
and 14%, respectively) and phenytoin (30% and 10%, respectively) (Wing & Miners
1985; Hansen et al. 1979). In addition, when trimethoprim and sulfamethoxazole were
coadministered, the AUC of S-warfarin was increased by 20% (O'Reilly 1980), and the
inhibition of the metabolic clearance of tolbutamide was more prominent (about 25%)
than when trimethoprim, and sulfamethoxazole were used alone (14% and 14%,
respectively) (Wing &Miners 1985).
3. Effects of albumin and cytosol on the enzyme kinetics of tolbutamide
hydroxylation and on inhibition of CYP2C9 by gemfibrozil
3.1 Effects of Hsa and Hlc on the enzyme kinetics
Addition of 0.5% Hsa (5 mg/ml) and Hlc (0.5 mg/ml) to the incubation media
significantly changed the enzyme kinetic parameters of tolbutamide, yielding the in
vivo Clh of tolbutamide, based on the co-addition of Hsa and Hlc to the incubations,
compable with the actual in vivo clearance values. Consistent findings have been
observed also with phenytoin, another CYP2C9 substrate (Ludden et al. 1997; Carlile
et al. 1999; Komatsu et al. 2000a). For example, addition of 2% or 4% bovine serum
albumin to microsomal incubation media changed the Km or Clint of phenytoin p-
hydroxylation, resulting in more accruate predictions of the in vivo values (Ludden et
al. 1997; Carlile et al. 1999). In addition, rat liver cytosol has been shown to stimulate
phenytoin oxidation in human liver microsomes (Komatsu et al. 2000a). To date, the
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mechanisms underlying these phenomena associated with albumin and cytosol are
unclear. It has been suggested that the binding affinity between the substrate and the
enzyme may be increased by albumin and cytosol, due to the conformational change of
the metabolic enzyme, or by sequestering some endogenous compounds that inhibit
CYP2C9. In any case, the mechanism of stimulation of CYP2C9 by cytosol seems not
to be related to binding of the substrate by cytosol, because the cytosol at 0.5 mg/ml
concentrations used in the present study, did not change the unbound fraction of
tolbutamide.
3.2 Effects of Hsa and Hlc on inhibition of CYP2C9 by gemfibrozil
The in vitro Ki value (6 µM) of gemfibrozil for CYP2C9 calculated using total drug
concentrations was substantially increased by Hlc (8 µM), Hsa (40 µM) or both (72
µM). However, considering the unbound substrate and inhibitor concentrations in the
calculation, the Ki (6 µM in the absence of Hsa and Hlc) was not markedly altered by
Hsa (4 µM), Hlc (8 µM) or both Hsa and Hlc (9 µM). Interestingly, although the
addition of Hsa may increase the binding affinity of tolbutamide to the enzyme (as
suggested by the Km values), it did not greatly change the unbound Ki value of
gemfibrozil. The underlying mechanism is unclear, it is assumed that both the binding
affinity of the substrate and the inhibitor to the enzyme were increased, resulting in
counterbalance, and minor changes of Ki.
As the present study cannot provide any mechanistic explanation for the observed
kinetic changes, and it is not known whether the effects of Hsa and Hlc are substrate-
or CYP form-specific, other substrates and other CYP forms need to be further
explored.
4. General discussion
Over the past decade, considerable progress has occurred in the development and
application of in vitro approaches using human tissues for assessing drug metabolism
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and interactions. As shown by the present studies, the effects of drugs on CYP forms
can be evaluated using microsomes and/or recombinant enzymes, and the in vivo
potential drug interactions can be quantitatively or qualitatively predicted based on the
in vitro data (Lin & Lu 1997; 2001; von Moltke et al. 1998). This information about
the evaluation of drugs safety is very useful in minimizing the economic losses of
pharmaceutical companies, as well as more effectively safeguarding the welfare of
patients. However, the complexity of human physiology contributes to the inaccuracy
of quantitative prediction of drug interactions. Therefore, it is important to carefully
set up the in vitro experimental systems and conditions that simulate the in vivo
situations. For example, optimal experimental conditions need to be established for
accurate estimation of the Ki value and suitable techniques need to be developed to
enable direct measurement of unbound inhibitor concentrations around the site of
target enzymes.
In general, one probe substrate, which always is the ''preferred'' probe reflecting
literature preference and extended period of use, is chosen for use in characterizing the
inhibition (determination of IC50 and Ki values) of each of the various CYPs in vitro
(Tucker et al. 2001). Considering that a weak correlation exists among some CYP3A
marker substrates (Kinirons et al. 1993; Stein et al. 1996; Thummel & Wilkinson
1998; Kenworthy et al. 1999), multiple structurally unrelated CYP3A4 probes, such as
midazolam and testosterone, have been recommended for used in the in vitro
assessment of CYP3A4-mediated drug interactions (Kenworthy et al. 1999; Tucker et
al. 2001). Furthermore, the correlations among other CYP marker substrates also need
to be considered in a comprehensive characterization of inhibition of CYP enzymes.
Drug metabolism and interactions are complex processes, which very often involve
several pathways and various enzyme systems. Besides CYP enzymes, phase II
enzymes such as the uridine diphosphate (UDP)-glucuronosyltransferases (UGT),
which catalyse the covalent addition of glucuronic acid to a wide range of lipophilic
chemicals, play a major role in the detoxification of many exogenous and endogenous
compounds (Burchell et al. 1995; 1998; Meech et al. 1997). Interactions involving
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glucuronidation mediated by UGT have been reported in a number of clinical and in
vitro studies (Markowitz et al. 2002; Hachad et al. 2002; Liston et al. 2001; Zhou et al.
2001; Ito et al. 2001). UGT is involved in the metabolism of valproic acid, gemfibrozil
and sulfamethoxazole, as shown in Table 3. It is well known that valproic acid can
inhibit the glucuronidation of drugs such as zidovudine, lamotrigine, phenobarbitone,
and 5-(p-Hydroxyphenyl)-5-phenylhydantoin (Trapnell et al. 1998; Hachad et al.
2002; Bernus et al. 1994; O'Leary et al. 1981). However, the effects of other drugs
tested on the activity of UGT are unknown, and have not been tested in previous
studies. Therefore, the role of UGT in drug metabolism and interactions could also be
considered.
In assessing the consequences of drug interaction, the identity of CYP forms
responsible for metabolising the involved drugs and the relative contribution of the
metabolic pathways being inhibited to the overall elimination of the drug must be
considered. The discrepancy of in vitro and in vivo may be caused by the differences in
the drug concentration used in vitro and observed in vivo (Lin & Lu 1998). Therefore,
the use of clinically relevant concentrations of inhibitor and substrate is very important
in the in vitro study. Other factors such as the in vitro systems chosen and mechanism
involved in drug interactions may also affect in vitro-in vivo extrapolations.
As the liver is the major site of the biotransformation of drugs, disease states,
especially diseases with hepatic involvement influence the metabolic capacity of the
individual and alter CYP-dependent drug elimination (Murray 1992; Tanaka 1998;
Rodighiero 1999; Sotaniemi et al. 2002). Furthermore, owing to extrahepatic drug
metabolism, drug transportation, interindividual variation and interethnic differences
in drug disposition, and numerous other complexities, the interpretation of in vitro
results to in vivo situations needs a good understanding of pharmacokinetic principles
and clinical considerations. Also there is a need for much more in vivo
pharmacokinetic data to validate in vitro data in the study of drug interactions.
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SUMMARY AND CONCLUSIONS
In the present study, the in vitro inhibitory effects of valproic acid, gemfibrozil,
isoniazid, trimethoprim and sulfamethoxazole on CYP forms were evaluated. In
addition, their potential in vivo drug-drug interactions were predicted. In Study V, the
effects of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and
on inhibition of CYP2C9 by gemfibrozil in human liver microsomes were examined.
The major findings and conclusions are as the follows:
1. Valproic acid inhibits the activity of CYP2C9 at clinically relevant concentrations
in human liver microsomes. Inhibition of CYP2C9 can explain some of the effects
of valproic acid on the pharmacokinetics of other drugs, such as phenytoin. Co-
administration of high doses of valproic acid with drugs that are primarily
metabolised by CYP2C9 may result in significant drug-drug interactions.
2. Gemfibrozil inhibits the activity of CYP2C9 at clinically relevant concentrations,
and this is the likely mechanism by which gemfibrozil interact with CYP2C9
substrate drugs, such as warfarin and glyburide. Gemfibrozil may also impair the
clearance of CYP2C19 and CYP1A2 substrates, but inhibition of other CYP forms
is unlikely.
3. Isoniazid at clinically relevant concentrations reversibly inhibits CYP2C19 and
CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19
and CYP3A4 in human liver microsomes. Co-administration of isoniazid and drugs
that are primarily metabolised by these CYP forms, particularly by CYP2C19 and
CYP3A4, may result in significant drug-drug interactions.
4. Trimethoprim can be used as selective inhibitors of CYP2C8 in in vitro studies. In
humans, trimethoprim may inhibit the activities of CYP2C8.
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5. Sulfamethoxazole is a selective inhibitor of CYP2C9 in vitro. The inhibition of
CYP2C9 activity by sulfamethoxazole may be the mechanism involved in the
drug-drug interactions between sulfamethoxazole and the substrates of CYP2C9.
6. Addition of Hsa and Hlc to microsomal incubations substantially changed the
enzyme kinetic estimates of tolbutamide. The predicted value of the in vivo Clh of
tolbutamide, based on the co-addition of Hsa and Hlc to the incubations, showed
good agreement with actual in vivo clearance values. However, addition of Hsa and
Hlc to the microsomal incubations only slightly altered the in vitro inhibitory effect
of gemfibrozil on tolbutamide hydroxylase activity when unbound drug
concentrations were considered. The present findings suggest that addition of both
substrates to the microsomal incubations may yield predictions which are more
comparable with the in vivo results.
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